{"study_id": 21590, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to develop a novel immunosensor for detecting HSP70, a potential biomarker for monitoring therapeutic response during anticancer therapy, using Au@MnO2/MoO3 nanocomposites.", "results_summary": "The immunosensor demonstrated a linear response range of 0.001 to 1000 ng mL-1 with a detection limit of 0.17 pg mL-1 and effectively detected HSP70 in a lung adenocarcinoma cell line post-Paclitaxel treatment.", "population_specificity": "Lung adenocarcinoma cell line (in vitro study).", "effective_dosage": "Not applicable (nanocomposite-based sensor study).", "study_duration": "Not specified (single measurement study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:00.509877+00:00"}
{"study_id": 21587, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the antibacterial activity of S, N-doped Graphene Quantum Dots (GQDs) modified with L-cysteine as a light-triggered antibacterial agent.", "results_summary": "L-cysteine-modified GQDs demonstrated strong antibacterial activity, with a minimum inhibitory concentration (MIC) as low as 125 \u03bcg/mL against S. aureus, E. faecalis, and E. coli after 1 hour of blue light exposure. The study confirmed successful modification of GQDs with L-cysteine, introducing S and N atoms into the structure.", "population_specificity": "Bacterial strains (8 tested, including S. aureus, E. faecalis, and E. coli)", "effective_dosage": "125 \u03bcg/mL (MIC)", "study_duration": "1 and 6 hours of blue light exposure", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:00.687400+00:00"}
{"study_id": 21588, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the in vitro effect of a fixed combination of N-acetyl-L-cysteine (NAC) and dry propolis extract on biofilm formation and eradication in bacterial species isolated from chronic upper respiratory tract infections.", "results_summary": "The NAC/propolis combination showed synergistic effects (51.7% of strains), inhibited biofilm formation at subinhibitory concentrations, and completely eradicated biofilms at suprainhibitory concentrations across all tested bacterial strains.", "population_specificity": "Adults with chronic rhinosinusitis (48) and chronic otitis media (29), and children with chronic adenoiditis (33).", "effective_dosage": "Subinhibitory concentrations (0.625-0.156 mg/mL to 10-2.5 mg/mL NAC + 0.062-0.016 mg/mL to 1-0.25 mg/mL propolis); suprainhibitory concentrations (2.5-10 mg/mL to 40-160 mg/mL NAC + 0.25-1 mg/mL to 4-16 mg/mL propolis).", "study_duration": "Not specified (in vitro study).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:03.036616+00:00"}
{"study_id": 21593, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-acetyl-L-cysteine (NAC) could reverse desipramine-induced eryptosis (programmed erythrocyte death).", "results_summary": "NAC significantly reversed desipramine-induced eryptosis, with the highest inhibitory effect observed when combined with nitric oxide donor sodium nitroprusside (SNP). The order of treatment (NAC before or after desipramine) did not influence its inhibitory effect.", "population_specificity": "Erythrocytes (red blood cells) in vitro.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:07.127074+00:00"}
{"study_id": 21592, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of L-Cysteine metabolism in DCVC toxicity and whether pharmacological modifiers like NAC and AOAA could mitigate this toxicity in human placental trophoblast cells.", "results_summary": "NAC and AOAA failed to mitigate DCVC-induced toxicity, with NAC exacerbating some effects. Syncytialized cells showed higher CCBL activity, suggesting increased sensitivity to DCVC toxicity.", "population_specificity": "Human placental trophoblast BeWo cells (unsyncytialized, undergoing syncytialization, and syncytialized).", "effective_dosage": "NAC at 5 mM, AOAA at 1 mM, DCVC at 5-50 \u00b5M.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:07.525747+00:00"}
{"study_id": 21596, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to develop a user-friendly, high-performance, and cost-effective fluorescence detection method for L-Cysteine using AgNP/SWCNTs and DNA-AgNCs.", "results_summary": "The study successfully developed a self-cascade system for detecting L-Cysteine, demonstrating high sensitivity and applicability in pharmaceutical, beverage, and serum samples. The method showed potential for medical diagnosis and food monitoring.", "population_specificity": "Not specified (in vitro study)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:07.583079+00:00"}
{"study_id": 21591, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects and mechanisms of L-Cysteine hydrochloride (L-CH) on inhibiting Aspergillus flavus growth and aflatoxin B1 (AFB1) biosynthesis.", "results_summary": "L-CH significantly inhibited A. flavus mycelial growth, altered morphology, and reduced AFB1 synthesis by inducing glutathione synthesis and scavenging reactive oxygen species. RNA-Seq analysis showed L-CH downregulated key genes involved in AFB1 production and fungal development.", "population_specificity": "Aspergillus flavus (fungal model)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:07.996631+00:00"}
{"study_id": 21597, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of N-acetyl-l-cysteine-derived carbonized polymer dots (NAC-CPDs) as an antioxidative and osteogenic therapy for periodontitis.", "results_summary": "NAC-CPDs effectively scavenged reactive oxygen species (ROS), promoted osteogenic differentiation in human periodontal ligament cells, and reduced alveolar bone resorption in periodontitis mice by modulating the Keap1/Nrf2 pathway.", "population_specificity": "Human periodontal ligament cells (hPDLCs) and periodontitis mice.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:08.375221+00:00"}
{"study_id": 21595, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether L-Cysteine (L-cys) enhances the degradation of acetamiprid in a photo-Fenton process by accelerating the Fe(III) to Fe(II) cycle.", "results_summary": "L-Cysteine significantly improved the degradation efficiency of acetamiprid in the photo-Fenton process by boosting reactive oxygen species (\u2022OH and 1O2) and facilitating electron transfer, leading to the breakdown of acetamiprid into less toxic molecules.", "population_specificity": "Not applicable (in vitro study using synthesized materials and chemicals).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:08.425280+00:00"}
{"study_id": 21594, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of L-Cysteine on reducing browning, lignification, and improving antioxidant activity in loquat fruit during cold storage and shelf life.", "results_summary": "The study found that 0.05% L-Cysteine effectively reduced weight loss, browning, decay, and lignin content while preserving soluble solids, sugar, acidity, and vitamin C. It also increased antioxidant compounds and delayed senescence in loquat fruit.", "population_specificity": "'Zaozhong No. 6' loquat fruit", "effective_dosage": "0.05% L-Cysteine", "study_duration": "40 days (35 days cold storage + 5 days shelf life)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:09.110453+00:00"}
{"study_id": 21598, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether N-acetyl-L-cysteine (NAC) could inhibit HPV-positive cell proliferation and reduce cervical carcinogenesis.", "results_summary": "NAC at 1.5 mM promoted apoptosis, reduced cell growth, and suppressed tumor growth in xenograft models by inhibiting HPV16 E7 expression, HIF-1\u03b1, and Akt activation.", "population_specificity": "HPV-positive cervical cancer cell lines (SiHa, HeLa), HPV-negative cell line (C33A), and immortalized human cervical keratinocyte cells (S12).", "effective_dosage": "1.5 mM", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:10.554006+00:00"}
{"study_id": 21603, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of L-cysteine in modulating oxidative stress and CHIKV infection in Aedes aegypti mosquitoes.", "results_summary": "Dietary L-cysteine supplementation restricted CHIKV infection and enhanced GST activity, reducing oxidative damage during infection. Silencing genes involved in taurine and hypotaurine synthesis modulated CHIKV infection and redox biology.", "population_specificity": "Aedes aegypti mosquitoes", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:15.244433+00:00"}
{"study_id": 21604, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the protective effect of N-acetyl-L-cysteine (NAC) on busulfan-induced testicular dysfunction in mice and explore its mechanism of action.", "results_summary": "NAC administration partially reversed busulfan-induced testicular damage, improving testis weight, sperm quality, hormone levels, and oxidative stress markers while enhancing Nrf2 and HO-1 mRNA expression.", "population_specificity": "C57BL/6 male mice", "effective_dosage": "10 mg/kg daily", "study_duration": "35 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:15.711677+00:00"}
{"study_id": 21599, "supplement_id": 1267, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of L-Cysteine (CYS) as a bioreducing/capping/gel-forming agent in synthesizing silver nanoparticles (AgNPs) and silver nanoclusters (AgNCs) for antibacterial and antibiofilm applications.", "results_summary": "The study found that CYS-AgNPs systems demonstrated high antibacterial activity against common bacteria and complete inhibition of biofilm formation for Acinetobacter baumannii and Pseudomonas aeruginosa at concentrations of 20-40 \u03bcM, with low toxicity to normal human cells.", "population_specificity": "In vitro testing on bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa) and normal human cells (erythrocytes, fibroblasts, macrophages).", "effective_dosage": "10-100 \u03bcM (MIC range), 20-40 \u03bcM (biofilm inhibition).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:16.694504+00:00"}
{"study_id": 21601, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to investigate how S-(1,2-dichlorovinyl)-l-cysteine (DCVC), a metabolite of trichloroethylene, affects energy metabolism and amino acid abundance during syncytialization in BeWo cells.", "results_summary": "DCVC treatment during syncytialization decreased several metabolites, including oleic acid, aspartate, and proline, but did not increase any measured metabolite. The study also found changes in energy metabolism and amino acid pathways, suggesting potential mechanisms by which DCVC could impact syncytialization.", "population_specificity": "Human villous trophoblastic cell line (BeWo cells) modeling syncytialization in vitro.", "effective_dosage": "10 or 20 \u03bcM DCVC.", "study_duration": "48 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:16.714239+00:00"}
{"study_id": 21600, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of N-acetyl-L-cysteine (NAC) alone or combined with praziquantel (PZQ) on parasitological, hepatic, and oxidative stress markers in acute schistosomiasis.", "results_summary": "NAC reduced worm and egg burden, increased dead eggs in intestinal tissue, and improved liver function markers. Combined NAC+PZQ reduced granulomatous inflammation and oxidative stress markers more effectively than either treatment alone.", "population_specificity": "Mice infected with S. mansoni (acute schistosomiasis model).", "effective_dosage": "200 mg/kg/day NAC (orally), 100 mg/kg/day PZQ (orally).", "study_duration": "NAC administered until day 60; PZQ administered from day 45 to 49.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:17.210941+00:00"}
{"study_id": 21605, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the otoprotective effects of N-acetyl-L-cysteine (NAC) against hearing loss induced by amikacin (AMI) and furosemide (FUR) in a mouse model.", "results_summary": "NAC reversed AMI-induced hearing threshold decreases but did not affect FUR-induced hearing loss. The study suggests NAC may serve as an otoprotectant for patients receiving AMI alone or in combination with FUR.", "population_specificity": "Mouse model (experimental animals)", "effective_dosage": "500 mg/kg (intraperitoneal)", "study_duration": "Not specified", "interactions": "AMI and FUR (NAC reversed AMI-induced ototoxicity but not FUR-induced ototoxicity)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:17.576148+00:00"}
{"study_id": 21606, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if an L-Cysteine-modified electrode could effectively and selectively detect methotrexate (MTX) in pharmaceutical and blood serum samples.", "results_summary": "The study found that the p(L-Cys)/g-C3N4/GCE electrode demonstrated high stability, selectivity, and sensitivity for MTX detection, with good recovery values (>97.20%) and accuracy (RSD <5.11%) in blood serum samples from breast cancer patients. The electrochemical signal was enhanced due to a synergistic effect between g-C3N4 and L-cysteine.", "population_specificity": "Five breast cancer patients (ages 35\u201350) providing blood serum samples.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:20.173164+00:00"}
{"study_id": 21608, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-acetyl-l-cysteine (NAC) could improve glucose tolerance, insulin sensitivity, and reproductive outcomes in a drug-induced gestational diabetes mellitus (GDM) mouse model.", "results_summary": "NAC significantly improved glucose tolerance, insulin sensitivity, and lipid profiles in GDM mice, while also restoring litter size and reducing birth weight. It enhanced the expression of Nrf2/HO-1 in the liver, suggesting a role in restoring redox homeostasis.", "population_specificity": "Drug-induced gestational diabetes mellitus (GDM) mouse model.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:24.913938+00:00"}
{"study_id": 21607, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the roles of autophagy and cell phenotype in N-acetyl-l-cysteine (NAC) promoting the secretion of HSA-pFSH\u03b2 in Pichia pastoris.", "results_summary": "NAC slowed cell growth, altered cell wall composition, decreased vesicular pathway and autophagy-related gene expressions, and increased autophagy, particularly the Cvt pathway, mitophagy, and pexophagy. Disruption of the mitophagy receptor Atg32 inhibited HSA-pFSH\u03b2 production but did not affect NAC's promoting effect.", "population_specificity": "Pichia pastoris (a yeast species used in recombinant protein production)", "effective_dosage": "Not specified", "study_duration": "Up to 72 hours of NAC treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:25.263080+00:00"}
{"study_id": 21602, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine the antioxidant and anti-inflammatory effects of NAC at different doses and treatment durations in a model of COPD-related inflammation.", "results_summary": "NAC at low doses in chronic administration showed sustained antioxidant and anti-inflammatory effects, while acute high-dose NAC treatment produced a strong antioxidant and anti-inflammatory response. The study highlighted dose-dependent effects, with in vitro efficacy requiring higher concentrations than achievable in vivo.", "population_specificity": "A549 cells transfected with Poly (I:C) to model inflammatory responses.", "effective_dosage": "Different doses (specific amounts not stated) and treatment periods.", "study_duration": "Varied treatment periods (specific duration not stated).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:26.425889+00:00"}
{"study_id": 21609, "supplement_id": 1267, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effect of L-cysteine treatment on controlling postharvest brown rot in plum fruits and explore its potential biocontrol mechanisms.", "results_summary": "100 mg L-1 L-cysteine effectively controlled brown rot in plum fruits by inducing resistance, enhancing enzyme activities, increasing NADPH content, and improving antioxidant levels. The treatment activated defense-related responses against infection.", "population_specificity": "Postharvest plum fruits artificially inoculated with pathogens.", "effective_dosage": "1, 10, 100, and 1000 mg L-1 L-cysteine (100 mg L-1 was most effective).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:26.771061+00:00"}
{"study_id": 21612, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effectiveness of adding N-acetyl-L-cysteine (NAC) and decitabine to a modified BUCY conditioning regimen for improving outcomes in HSCT recipients with myeloid malignancies.", "results_summary": "The study found that Arm A (with NAC and decitabine) showed accelerated platelet recovery, lower relapse rates, and improved event-free survival compared to Arm B (standard mBUCY). Intracellular ROS levels were inversely correlated with platelet recovery, and fewer patients in Arm A exhibited excessive ROS.", "population_specificity": "Patients with myeloid malignancies undergoing hematopoietic stem cell transplant (HSCT).", "effective_dosage": "NAC administered from day -9 to +30 (exact dosage not specified).", "study_duration": "NAC was administered for 39 days (from day -9 to day +30).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:28.265629+00:00"}
{"study_id": 21610, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether N-Acetyl-L-cysteine (NAC) could attenuate oxidative stress injury in bone marrow endothelial cells (BMECs) and its potential therapeutic role in senile osteoporosis.", "results_summary": "NAC treatment reduced reactive oxygen species (ROS) overgeneration and apoptosis in BMECs in vitro and mitigated BMEC loss and bone mass decline in vivo, suggesting therapeutic potential for age-related osteoporosis.", "population_specificity": "Bone marrow endothelial cells (BMECs) in different age groups (in vivo and in vitro models).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:29.490096+00:00"}
{"study_id": 21611, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to analyze the interrelationship between nitric oxide (NO) and hydrogen sulfide (H2S) during pepper fruit ripening, focusing on the regulatory roles of L-cysteine desulfhydrase (LCD) and D-cysteine desulfhydrase (DCD).", "results_summary": "The study found that LCD and DCD activities were downregulated during ripening but were restored after NO treatment. In vitro analyses showed that NO donors, peroxynitrite, and reducing agents like L-cysteine inhibited specific LCD isozymes, suggesting redox adaptation as a hormesis phenomenon.", "population_specificity": "Non-climacteric pepper fruits at different ripening stages.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:30.696300+00:00"}
{"study_id": 21613, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-acetyl-L-cysteine (NAC) could enhance the degradation of ochratoxin A (OTA) by the antagonistic yeast Cryptococcus podzolicus Y3 and mitigate OTA toxicity.", "results_summary": "NAC significantly improved OTA degradation rates (100% at 1 day and 92.6% at 2 days) and promoted glutathione accumulation, though it temporarily reduced yeast viability and cell membrane integrity early in treatment. The antioxidant properties of NAC prevented lipid peroxidation, supporting its role in enhancing mycotoxin degradation.", "population_specificity": "Antagonistic yeast (Cryptococcus podzolicus Y3) in laboratory conditions.", "effective_dosage": "10 mM NAC", "study_duration": "2 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:33.635709+00:00"}
{"study_id": 21616, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the synthesis and potential applications of peptide amphiphiles (PAs) as drug carriers, particularly for cancer therapy, using L-Cysteine-derived structures.", "results_summary": "The study found that PAs self-assembled into micelles and hydrogels with pH-dependent properties, demonstrated controlled drug release, and showed cytotoxic effects on HeLa cells when loaded with cisplatin (CDDP).", "population_specificity": "In vitro (HeLa cells)", "effective_dosage": "13.5 \u03bcg/mL (PA2 blank micelles), 100 mg/mL (PA2 hydrogel)", "study_duration": "2 days (cell viability assay), 14 days (hydrogel degradation)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:34.789945+00:00"}
{"study_id": 21617, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetyl-L-cysteine (NAC) could mitigate the toxic effects of ZIF-8 on human vascular endothelial cells, particularly focusing on oxidative stress, apoptosis, and endothelial dysfunction.", "results_summary": "NAC effectively reduced ROS formation, cell apoptosis, LDH formation, and endothelial dysfunction caused by ZIF-8. It also inhibited the ZIF-8-induced increase in \u03b2-catenin and LEF1 protein expressions, suggesting a protective role via the Wnt/\u03b2-catenin pathway.", "population_specificity": "Human EA.hy926 vascular endothelial cells", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:34.979003+00:00"}
{"study_id": 21614, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the potential of L-Cysteine-coated magnetic iron oxide nanoparticles loaded with doxorubicin as an efficient drug delivery system for melanoma therapy.", "results_summary": "The study demonstrated that Fe3O4-L-Cys-Dox nanoparticles effectively delivered doxorubicin to melanoma cells, showing lower IC50 values compared to unloaded controls, and induced cell cycle arrest and apoptosis. The nanoparticles also exhibited pH-dependent drug release, with higher release rates in acidic conditions.", "population_specificity": "Mouse (B16F10) and human (A375) metastatic melanoma cells.", "effective_dosage": "200 \u00b5g/mL Fe3O4-L-Cys-Dox solution.", "study_duration": "Not specified (assessed effects at 3 h and 48 h post-treatment).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:35.401984+00:00"}
{"study_id": 21615, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the modulatory effect of N-Acetyl-l-Cysteine (NAC) on H2O2-oxidized Voltage Dependent Anion Channel (VDAC) to understand its antioxidant protection against oxidative stress.", "results_summary": "NAC suppressed VDAC conductance with an IC50 of \u223c1.04 \u03bcM and reversed H2O2-induced oxidative stress effects, reducing conductance by 33% when pre-incubated. In-silico studies indicated NAC binds to specific residues of VDAC, demonstrating its protective role against H2O2.", "population_specificity": "In vitro electrophysiological studies (not human or animal subjects).", "effective_dosage": "1 \u03bcM NAC (single concentration tested).", "study_duration": "Not specified (acute in vitro study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:36.097739+00:00"}
{"study_id": 21618, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether YPS1 and YPT7 gene disruption and N-acetyl-L-cysteine (NAC) supplementation synergistically reduce degradation of recombinant HSA-pFSH\u03b2 protein in Pichia pastoris.", "results_summary": "YPS1 gene disruption reduced degradation of HSA-pFSH\u03b2 and increased intact protein yield, with synergistic effects when combined with NAC supplementation. YPT7 gene disruption and NH4Cl treatment also influenced recombinant protein production.", "population_specificity": "Pichia pastoris (yeast model for recombinant protein production)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:36.325429+00:00"}
{"study_id": 21619, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of L-Cysteine pre-treatment on potato starch digestibility and structural changes when exposed to \u03b1-amylase.", "results_summary": "L-Cysteine pre-treatment increased starch hydrolysis (24.1% and 36.5% vs. 16.8% in native starch), reduced crystallinity, and altered thermal properties, indicating enhanced digestibility and structural degradation.", "population_specificity": "In vitro study (potato starch granules)", "effective_dosage": "150 mg/kg (PC1) and 300 mg/kg (PC2)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:37.251647+00:00"}
{"study_id": 21620, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine how N-acetyl-L-cysteine (NAC) affects tendon stem/progenitor cell (TSPC) functions and tendon repair in a rat model of Achilles tendon injury.", "results_summary": "NAC promoted TSPC proliferation, reduced oxidative stress, enhanced tendon-related protein expression (COL1A1, TNC, SCX, TNMD), and improved tendon repair in rats by modulating PI3K/AKT signaling.", "population_specificity": "Rat model of Achilles tendon injury and in vitro tendon stem/progenitor cells (TSPCs).", "effective_dosage": "500 \u00b5M NAC in vitro; dosage in vivo not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:39.240705+00:00"}
{"study_id": 21621, "supplement_id": 1267, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a novel bioadhesive material (CS-Cys) in enhancing corneal permeation and retention for ocular drug delivery.", "results_summary": "The study found that Dex-CS-Cys-cNLC improved corneal permeation and retention, prolonged drug action time, and effectively alleviated dry eye symptoms in rabbits without causing irritation.", "population_specificity": "Rabbit models of dry eye.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:40.634212+00:00"}
{"study_id": 21622, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether intranasal administration of N-acetyl-L-cysteine (NAC) combined with PEG-PCL-Tat nanocarriers could serve as an effective drug delivery system for ALS treatment.", "results_summary": "Intranasal NAC/PEG-PCL-Tat significantly prolonged the median survival of ALS model mice by 11.5 days and showed high distribution in the spinal cord, suggesting potential therapeutic efficacy for ALS.", "population_specificity": "Superoxide dismutase-1 G93A mutant transgenic mice (ALS model) and ddY mice (for tissue distribution analysis).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:43.262559+00:00"}
{"study_id": 21625, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of L-Cysteine on corticosterone-induced oxidative stress, behavioral deficits, and memory impairment in male rats.", "results_summary": "L-Cysteine administration improved antidepressant, anxiolytic, and memory-enhancing effects, likely due to enhanced antioxidant activity and normalized neurotransmission in the hippocampus. It also normalized elevated plasma corticosterone levels.", "population_specificity": "Male rats", "effective_dosage": "150 mg/kg/ml, administered orally", "study_duration": "28 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:43.335248+00:00"}
{"study_id": 21624, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the protective mechanism of N-Acetyl-Cysteine (NAC) combined with insulin on renal injury in dogs with diabetic nephropathy (DN).", "results_summary": "The study found that INS + NAC effectively reduced and stabilized blood glucose levels, regulated biochemical markers (UREA, CREA, fructosamine), reversed glomerular damage, restored mitochondrial homeostasis, and alleviated mitophagy in diabetic dogs.", "population_specificity": "Dogs with diabetic nephropathy.", "effective_dosage": "Not specified.", "study_duration": "4 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:43.557977+00:00"}
{"study_id": 21627, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether L-cysteine could modify symptom patterns in patients with chronic atrophic gastritis (CAG).", "results_summary": "L-cysteine treatment (300 mg daily) led to a statistically significant improvement in symptom scores (VAS) over 24 months compared to untreated controls, with no significant changes observed in the control group.", "population_specificity": "Patients with histological diagnosis of CAG (OLGA \u22651 with gastric corpus involvement).", "effective_dosage": "300 mg daily", "study_duration": "24 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:44.319089+00:00"}
{"study_id": 21623, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether L-Cysteine (L-Cys) could delay quality deterioration and extend the shelf life of fresh-cut button mushrooms by regulating oxidative metabolism and endogenous H2S production.", "results_summary": "L-Cys treatment significantly delayed browning, reduced weight loss, improved antioxidant enzyme activities, and enhanced endogenous H2S production, while also modulating reactive oxygen species metabolism and sulfur metabolism pathways. Additional treatment with propargylglycine reduced L-Cys effects, suggesting its role in H2S-mediated mechanisms.", "population_specificity": "Fresh-cut button mushrooms (Agaricus bisporus)", "effective_dosage": "0.25 g/L L-Cys", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:44.543591+00:00"}
{"study_id": 21626, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether the combination of cefditoren (CDN) and N-acetyl-l-cysteine (NAC) could effectively inhibit and treat pneumococcal biofilms, including those formed by antibiotic-resistant strains.", "results_summary": "The study found that CDN and NAC synergistically inhibited bacterial growth, destroyed biofilm biomass, reduced bacterial adhesion to lung epithelial cells, and effectively cleared multidrug-resistant pneumococcal infections in mice. The combination showed strong antimicrobial effects in both prevention and treatment assays.", "population_specificity": "Mice with acute pneumococcal pneumonia and pneumococcal biofilms from clinical isolates.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:44.817087+00:00"}
{"study_id": 21628, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the neuroprotective effects of N-acetyl-L-cysteine (NAC) against methylmercury-induced neurotoxicity and its regulation of oxidative stress and autophagy pathways.", "results_summary": "Pretreatment with NAC significantly prevented methylmercury-induced oxidative stress and autophagy mediated by PI3K/AKT/mTOR or AMPK/TSC2/mTOR pathways, suggesting its protective role in neurotoxicity.", "population_specificity": "Rats (animal study)", "effective_dosage": "1 mmol/kg NAC", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:47.461416+00:00"}
{"study_id": 21629, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether combining N-acetyl-L-cysteine (NAC) with moxifloxacin-loaded nanoparticles could enhance antibiofilm efficacy against Staphylococcus aureus.", "results_summary": "NAC-loaded nanosystems significantly reduced S. aureus biofilm viability and biomass, and combining them with moxifloxacin-loaded nanoparticles further increased antibiofilm efficacy.", "population_specificity": "Bacterial biofilms of Staphylococcus aureus, particularly those formed on implants and polyurethane catheters.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:48.606805+00:00"}
{"study_id": 21631, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether S-nitroso-L-cysteine (CSNO) could improve insulin sensitivity, glucose uptake, and cardiac function in diabetic cardiomyopathy (DCM).", "results_summary": "CSNO treatment enhanced insulin-dependent and insulin-independent glucose uptake, activated insulin signaling, promoted GLUT4 translocation, and protected cardiomyocytes from high glucose-induced injury by reducing autophagy, mitochondrial impairment, and oxidative stress. Nebulized CSNO also improved cardiac function and reduced myocardial fibrosis in diabetic mice.", "population_specificity": "Diabetic mice with cardiomyopathy (DCM).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:51.654705+00:00"}
{"study_id": 21630, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of L-cysteine combined with protease as an environmentally friendly shrink-proof treatment for wool fibers.", "results_summary": "The study found that L-cysteine effectively reduced and destroyed the wool scale layer, and when combined with protease, it significantly reduced felting (from 135.86 kg/m3 to 48.65 kg/m3) while preserving thermal and mechanical properties. The treatment was rapid, effective, and less polluting compared to traditional methods.", "population_specificity": "Wool fibers (not human or animal subjects).", "effective_dosage": "9 g/L L-cysteine and 1 g/L protease 16L, padded five times at 50 \u00b0C with 30 s immersion per cycle.", "study_duration": "Not specified (intervention duration not detailed in abstract).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:52.361668+00:00"}
{"study_id": 21634, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to develop a Poloxamer hydrogel with Chitosan-N-acetyl-L-cysteine (CNAC) nanoparticles to enhance the loading and sustained intravitreal delivery of Avastin, improving its efficacy for treating diabetic retinopathy.", "results_summary": "The optimized hydrogel demonstrated sustained and controlled drug release over 256 hours, with 97% of dexamethasone released within 18 hours. In vivo results showed improved efficacy in treating diabetic retinopathy compared to free Avastin.", "population_specificity": "Not specified (likely animal or in vitro models, based on context).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:52.591117+00:00"}
{"study_id": 21635, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether dosage and duration of N-acetyl-L-cysteine (NAC) treatment could improve metabolic outcomes, beta-cell health, and pancreatic stellate cell quiescence in high-fat diet-induced obese diabetic mice.", "results_summary": "NAC treatment significantly improved glucose tolerance, insulin sensitivity, and beta-cell function while reducing oxidative stress and pancreatic stellate cell activation in obese diabetic mice, with longer treatment durations showing greater efficacy.", "population_specificity": "Male C57BL/6N mice fed a high-fat diet to induce obesity and type II diabetes.", "effective_dosage": "Administered in drinking water (specific concentration not provided).", "study_duration": "Preventative treatment for 23 weeks or intervention treatment for 10 or 18 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:53.275303+00:00"}
{"study_id": 21632, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine the anticancer effect of a pharmacological pair involving S-propyl-L-cysteine sulfoxide (propiin) and C115H MGL-Dz against various solid tumor types in vitro and in vivo.", "results_summary": "The study found that the combination of C115H MGL-Dz and propiin significantly reduced tumor growth in multiple cancer cell lines (colon, pancreatic, and prostate) both in vitro (low IC50 values) and in vivo (notable tumor growth inhibition percentages).", "population_specificity": "Colon (HT29, COLO205, HCT116), pancreatic (Panc1, MIA-PaCa2), and prostate (22Rv1, DU-145, PC3) cancer cell lines in vitro; BALB/c nude mice with subcutaneous xenografts in vivo.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:53.387855+00:00"}
{"study_id": 192347, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to explore the potential mechanisms of L-Cysteine and its metabolites (GSH and H2S) in managing anxiety and related disorders.", "results_summary": "L-Cysteine demonstrated anxiolytic, antidepressant, and memory-improving effects, with its metabolites (glutathione and hydrogen sulfide) alleviating anxiety through distinct molecular mechanisms. Long-term administration enhanced antioxidant functions in the CNS, while depletion increased oxidative stress in the brain.", "population_specificity": "Not specified (general anxiety disorder context implied).", "effective_dosage": "Not specified.", "study_duration": "Long-term (specific duration not provided).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:56.383157+00:00"}
{"study_id": 192350, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether L-cysteine could prevent or alleviate alcohol/acetaldehyde-related hangover symptoms, including nausea, headache, stress, and anxiety.", "results_summary": "L-cysteine was found to prevent or alleviate hangover symptoms, with 1200 mg effective for nausea and headache, and 600 mg effective for stress and anxiety. The study suggests L-cysteine may reduce the need for drinking the next day and lower the risk of alcohol addiction.", "population_specificity": "Healthy male volunteers with prior experience of hangover and/or headache.", "effective_dosage": "600 mg and 1200 mg doses were tested.", "study_duration": "Alcohol was consumed over 3 hours; intervention duration not specified beyond this.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:56.789360+00:00"}
{"study_id": 192351, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine whether combining L-Cysteine with other antioxidants and UVB phototherapy improves oxidative stress biomarkers and repigmentation in vitiligo patients.", "results_summary": "The study found that the combined therapy, including L-Cysteine, increased Asc* radical levels, decreased MDA products, and led to initial repigmentation in vitiligo spots, suggesting improved oxidant-antioxidant balance.", "population_specificity": "Vitiligo patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:19:59.590717+00:00"}
{"study_id": 192354, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to explore the role of N-Acetyl-L-Cysteine (NAC) supplementation in modulating the effects of oxygen availability changes on HIF-1\u03b1-regulated gene expression, including EPO production.", "results_summary": "The abstract suggests that NAC supplementation may assist in manipulating hyperoxic and hypoxic states to influence HIF-1\u03b1-regulated gene synthesis, such as EPO, but specific outcomes or mechanisms are not detailed.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not provided.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:01.383608+00:00"}
{"study_id": 192353, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of N-acetyl-L-cysteine (NAC) supplementation on the transsulfuration pathway and antioxidant capacity in HIV+ patients compared to healthy controls.", "results_summary": "NAC supplementation increased remethylation and normalized transsulfuration in HIV+ patients, boosting plasma glutathione (GSH) levels above controls but failing to restore normal cysteine (Cys) levels due to higher consumption in GSH and taurine synthesis pathways.", "population_specificity": "20 non-HIV+ control subjects and 12 HIV+ HAART-treated patients.", "effective_dosage": "1 g/day of NAC.", "study_duration": "7 days per dietary situation (NAC supplementation vs. usual diet).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:01.541046+00:00"}
{"study_id": 192355, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate whether L-Cysteine could serve as an adjuvant therapy for type-2 diabetes by improving glucose metabolism and insulin signaling.", "results_summary": "The study found that L-Cysteine and cysteine-rich whey protein improved glucose metabolism in diabetic animals and type-2 diabetic patients, suggesting potential benefits as an adjuvant therapy. Further research is needed to confirm its effects on glycemia and vascular inflammation in diabetic populations.", "population_specificity": "Diabetic animals and type-2 diabetic patients.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:01.608911+00:00"}
{"study_id": 192352, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine whether L-Cysteine (via arginase inhibition) improves microvascular function in young African Americans compared to Caucasian Americans.", "results_summary": "The study found that arginase inhibition with L-Cysteine (BEC) did not improve microvascular responses to local heating in young African Americans, unlike L-arginine supplementation. The response remained unchanged compared to the control site.", "population_specificity": "Young African American and Caucasian American adults.", "effective_dosage": "5.0 mM (S)-(2\u2011boronoethyl)-l-cysteine-HCL (BEC) combined with 5.0 mM N\u03c9-hydroxy-nor-l-arginine (nor-NOHA), infused at 2.0 \u03bcl/min.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:01.951089+00:00"}
{"study_id": 21633, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the effectiveness of gamma-L-Glutamyl-L-Cysteine coated nanoparticles encapsulating Ropinirole hydrochloride (C-Rp-NPs) for targeted treatment of ischemic stroke and reperfusion injury.", "results_summary": "The study found that C-Rp-NPs enhanced brain targeting, extended drug retention, and significantly improved therapeutic outcomes at 1000 times lower concentration compared to free Ropinirole solution, reducing neuronal damage, oxidative stress, and neuroinflammation.", "population_specificity": "Transient middle cerebral artery occlusion (tMCAO) model (animal study).", "effective_dosage": "Not specified (1000 times less concentration than free Rp solution).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:03.043127+00:00"}
{"study_id": 192356, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine if chromium dinicocysteinate (CDNC), a complex of chromium and L-cysteine, reduces oxidative stress, vascular inflammation, and glycemia in type 2 diabetic subjects.", "results_summary": "CDNC supplementation significantly reduced insulin resistance, protein oxidation, and TNF-\u03b1 levels compared to baseline, but had no significant effect on HbA1c or glucose levels. Chromium picolinate (CP) showed no significant changes in these markers.", "population_specificity": "Type 2 diabetic subjects (74 completed the study).", "effective_dosage": "Not specified in the abstract.", "study_duration": "3 months of daily supplementation after a 1-month placebo stabilization period.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:05.413849+00:00"}
{"study_id": 192357, "supplement_id": 1267, "safety_score": "85", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine whether supplementing with L-Cysteine and pantothenic acid could increase muscle CoASH content and thereby impact fuel metabolism and exercise performance in humans.", "results_summary": "The study found that supplementation with L-Cysteine and pantothenic acid did not alter muscle CoASH content, fuel metabolism, or exercise performance compared to placebo. No significant differences in outcomes were observed between the supplemented and control groups.", "population_specificity": "Eight healthy male volunteers (age 22.9 \u00b1 1.4 yr, BMI 24.2 \u00b1 1.5 kg/m\u00b2).", "effective_dosage": "1.5 g/day of L-Cysteine, combined with 1.5 g/day of D-pantothenic acid.", "study_duration": "1 week of supplementation prior to testing.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:05.997690+00:00"}
{"study_id": 192358, "supplement_id": 1267, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether a cysteinate complex of chromium (CDNC) was more effective than L-cysteine alone or other chromium forms in improving glucose metabolism and reducing vascular inflammation in diabetic rats.", "results_summary": "L-cysteine (LC) alone showed significantly less or no effect on biomarkers like blood glucose, HbA1, CRP, and oxidative stress compared to the CDNC group. LC did not significantly impact liver signaling pathways (NF\u03baB, Akt, IRS-1) or inflammation markers.", "population_specificity": "Zucker diabetic fatty (ZDF) rats, a model for type 2 diabetes.", "effective_dosage": "Equimolar L-cysteine (LC, 1 mg/kg body weight, daily oral gavage).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:09.129124+00:00"}
{"study_id": 47428, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate whether sitagliptin could mitigate L-dopa-induced dyskinesia (LID) in a Parkinson's disease mouse model.", "results_summary": "Sitagliptin combined with L-dopa significantly reduced abnormal involuntary movement scores in 6-OHDA-lesioned mice, with proteomic analysis suggesting improved mitochondrial function and reduced neuronal activity in the striatum.", "population_specificity": "6-OHDA-lesioned mice modeling Parkinson's disease.", "effective_dosage": "Not specified.", "study_duration": "11 consecutive days of L-dopa treatment with or without sitagliptin.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:10.455966+00:00"}
{"study_id": 47424, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to analyze the spatial profile of L-DOPA-induced gene expression in the forebrain of mice with progressive dopaminergic neuron loss to understand its effects on motor and nonmotor symptoms of Parkinson's disease.", "results_summary": "L-DOPA treatment had widespread effects on gene expression beyond dopamine-dependent movement control areas, with pronounced changes in the dorsal cortex and striatum (e.g., increased Fos, Egr1, Junb) and decreased transcripts in the piriform cortex and claustrum. The study identified 121 regulated genes, revealing anatomical complexity in L-DOPA's effects.", "population_specificity": "Mice with inducible progressive loss of dopaminergic neurons (TIF-IADATCreERT2 strain).", "effective_dosage": "Not specified", "study_duration": "14 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:10.569712+00:00"}
{"study_id": 47425, "supplement_id": 1268, "safety_score": "40", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to provoke L-DOPA-induced dyskinesia (LID) in parkinsonian mice using an AAV-mediated \u03b1-synuclein overexpression model and explore associated histologic features.", "results_summary": "LID was observed in 3 out of 19 mice at 10 mg/kg L-DOPA and 14 mice at 25 mg/kg. The study found correlations between LID severity and reductions in TH-positive neurons and striatal fibers.", "population_specificity": "Wild-type mice with AAV-mediated \u03b1-synuclein overexpression in the substantia nigra.", "effective_dosage": "10 mg/kg daily for one week, then 25 mg/kg daily for another week.", "study_duration": "Two weeks (one week per dosage).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:10.687497+00:00"}
{"study_id": 47429, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the effects of L-Dopa on arm swing movements during gait in Parkinson's disease patients across different disease stages and therapeutic conditions.", "results_summary": "L-Dopa restored patterns of arm swing movements in PD patients, with kinematic improvements correlating with reduced bradykinesia and rigidity severity. The study found that arm swing abnormalities worsened with disease progression but responded positively to dopaminergic therapy.", "population_specificity": "40 Parkinson's disease patients (20 early-stage, 20 mid-advanced) and 20 healthy subjects.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:11.173689+00:00"}
{"study_id": 47426, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 82, "study_goal": "The researchers aimed to explore the potential of an identified PD-related covariance pattern (ASL-PDRP) for predicting motor progression and L-DOPA reactivity reduction in Parkinson's disease patients.", "results_summary": "The ASL-PDRP was associated with motor symptoms and could predict UPDRS III progression. Higher ASL-PDRP expression correlated with slower L-DOPA reactivity reduction in PD patients with axial symptoms.", "population_specificity": "179 PD patients and 62 normal controls in the original cohort; 36 PD and 19 normal controls in the validation cohort.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:11.354251+00:00"}
{"study_id": 47430, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 92, "quality_score": 85, "study_goal": "The researchers aimed to determine the effects of AMF and PGPR inoculation on L-Dopa content in faba beans, focusing on its potential for Parkinson's disease prevention.", "results_summary": "AMF inoculation significantly increased L-Dopa content by 92% in faba bean pods, suggesting enhanced biofortification potential for Parkinson's disease prevention.", "population_specificity": "Faba bean plants treated with AMF and PGPR.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:13.010226+00:00"}
{"study_id": 47431, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the roles of NF-\u03baB and TNF-\u03b1 signalling pathways in levodopa-induced dyskinesia (LID) pathophysiology and potential therapeutic approaches targeting these mechanisms.", "results_summary": "Chronic levodopa treatment leads to aberrant neuroplasticity and neuroinflammation, involving NF-\u03baB activation and increased TNF-\u03b1 production, exacerbating dopaminergic neuron loss. Several compounds, including agmatine, resveratrol, doxycycline, fasudil, CB2 receptor agonists, and hydrogen gas, show efficacy in mitigating LID by modulating these pathways.", "population_specificity": "Patients with Parkinson's disease experiencing long-term levodopa treatment-induced dyskinesia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:14.655079+00:00"}
{"study_id": 47436, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine the mechanisms underlying L-Dopa-induced dyskinesia (LID) and identify the primary causal factors for its emergence in Parkinson's disease patients.", "results_summary": "The study found that striatal dopamine denervation is the major causal factor for LID, while \u03b1-synuclein aggregates do not play a significant role. It also supported maladaptive basal ganglia plasticity as the main pathophysiological mechanism underlying LID.", "population_specificity": "Parkinson's disease patients and four animal models.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:17.883948+00:00"}
{"study_id": 47433, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the cortical mechanisms underlying L-Dopa treatment in Parkinson's disease patients using MEG recordings and HMM analysis.", "results_summary": "L-Dopa significantly increased the motor state of HMM and power in the motor area for both high and low \u03b2 bands, with high \u03b2 motor state in the medoff condition correlating with UPDRS III scores.", "population_specificity": "21 Parkinson's disease patients treated with medication.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:18.083377+00:00"}
{"study_id": 47435, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether chemogenetic inhibition of serotonin (5-HT) raphe-projecting neurons could reduce L-Dopa-induced dyskinesia (LID) and Parkinson's disease-associated psychosis (PDAP) in a rat model.", "results_summary": "Chemogenetic inhibition of 5-HT raphe-projecting cells significantly reduced LID without impairing motor function or worsening sensorimotor gating deficits, suggesting a potential therapeutic approach for managing L-Dopa side effects.", "population_specificity": "6-OHDA-lesioned rats (Parkinson's disease model).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:18.532913+00:00"}
{"study_id": 47438, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to demonstrate L-DOPA's therapeutic effect in regulating systemic immune response and improving functional deficits in mice with ischemic stroke.", "results_summary": "L-DOPA attenuated striatonigral degeneration, reversed motor impairment, increased IL-13, and reduced IFN-\u03b3 in infarct lesions. IL-13 activation of microglia phagocytosis contributed to neuroprotection.", "population_specificity": "Mice with ischemic stroke induced by middle cerebral artery occlusion (MCAO).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:18.568077+00:00"}
{"study_id": 47432, "supplement_id": 1268, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the feasibility, safety, and efficacy of intracerebroventricular administration of anaerobic dopamine (A-dopamine) compared to optimized oral antiparkinsonian therapy in Parkinson's disease patients.", "results_summary": "The study found that A-dopamine significantly reduced the percentage of time with dyskinesia or bradykinesia compared to oral treatment alone, with a median within-patient difference of -10.4. Home diaries also showed significant improvement, suggesting better symptom control with A-dopamine.", "population_specificity": "9 patients with Parkinson's disease (phase 2 study), with an initial phase 1 study involving 12 patients.", "effective_dosage": "Not specified", "study_duration": "1 month for each treatment (A-dopamine and oral therapy) in a crossover design.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:18.938101+00:00"}
{"study_id": 47437, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 92, "quality_score": 85, "study_goal": "The researchers aimed to develop a simplified cascade for synthesizing hydroxytyrosol from L-DOPA using engineered enzymes to improve efficiency and thermal stability.", "results_summary": "The study achieved a 256.8-fold increase in enzyme activity for L-DOPA conversion and a 98.2% molar conversion rate of hydroxytyrosol from L-DOPA, the highest reported. The engineered enzymes also demonstrated improved thermal stability.", "population_specificity": "In vitro enzymatic study (no human or animal subjects).", "effective_dosage": "32 mM L-DOPA used in the reaction.", "study_duration": "5-hour reaction time.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:19.106433+00:00"}
{"study_id": 47439, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of cholinergic transmission at muscarinic M4 receptor synapses in dopamine-depleted mice and its impact on motor deficits and levodopa-induced dyskinesia (LID).", "results_summary": "The study found that cholinergic transmission at M4 receptor synapses was decreased in dopamine-depleted mice due to reduced postsynaptic M4 receptor function. Restoring M4 transmission partially alleviated motor deficits and LID, revealing a prokinetic effect in addition to the known antikinetic role of M4 receptors.", "population_specificity": "Dopamine-depleted mice (animal model of Parkinson's disease).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:21.284950+00:00"}
{"study_id": 47440, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to investigate the role of SERT knockdown in reducing L-DOPA-induced dyskinesia (LID) and its effects on motor performance and gene expression in a Parkinson's disease model.", "results_summary": "SERT knockdown significantly and durably reduced LID and L-DOPA-induced striatal cFOS mRNA without affecting L-DOPA efficacy, suggesting SERT as a therapeutic target for LID.", "population_specificity": "Hemiparkinsonian, stably dyskinetic rats (N = 68)", "effective_dosage": "Not specified", "study_duration": "2 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:22.220213+00:00"}
{"study_id": 47441, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of L-Dopa in managing hyperprolactinemia in patients with DHPR deficiency and assess its limitations compared to cabergoline.", "results_summary": "The study found that L-Dopa supplementation normalized prolactin levels initially but was insufficient for long-term suppression, leading to lactotroph hypertrophy and prolactinoma development. Cabergoline was more effective due to its stronger D2R affinity and longer half-life.", "population_specificity": "Patients with DHPR deficiency presenting with hyperprolactinemia and amenorrhea.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:25.255553+00:00"}
{"study_id": 47443, "supplement_id": 1268, "safety_score": "30", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to investigate the addictive-like properties of L-Dopa in a Parkinson's disease mouse model and explore the role of abnormal dopamine D1 receptor signaling in dopamine dysregulation syndrome (DDS).", "results_summary": "L-Dopa induced locomotor sensitization and conditioned place preference in 6-OHDA-lesioned mice, indicating addictive-like behavior. These effects were linked to abnormal D1R signaling and were counteracted by D1R antagonist SCH23390 or chemogenetic inactivation of D1R-expressing neurons.", "population_specificity": "6-OHDA-lesioned mice modeling Parkinson's disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:26.877635+00:00"}
{"study_id": 47444, "supplement_id": 1268, "safety_score": "60", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to scrutinize the rate-limiting step of L-DOPA autoxidation in aqueous solution to understand its oxidative stress implications in Parkinson's disease.", "results_summary": "The study found that L-DOPA autoxidation involves an intramolecular Michael addition with a proton transfer, yielding a calculated free energy barrier of 30.93 \u00b1 1.12 kcal/mol, which aligns reasonably with experimental data. This confirms the mechanism's validity and the methodology's applicability for studying L-DOPA autoxidation kinetics in proteins.", "population_specificity": "Not specified (in vitro study)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:26.981544+00:00"}
{"study_id": 47442, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of sildenafil (a PDE5 inhibitor) combined with L-DOPA on asymmetric behavior and dopamine/serotonin metabolism in a rat model of Parkinson's disease.", "results_summary": "Acute sildenafil combined with L-DOPA increased contralateral rotations, while chronic low-dose sildenafil with L-DOPA reduced rotations. Combined treatment increased dopamine concentration but altered its catabolism differently in brain regions.", "population_specificity": "Unilaterally 6-OHDA-lesioned rats (a Parkinson's disease model).", "effective_dosage": "L-DOPA (12.5 mg/kg), sildenafil (2 mg/kg and 6 mg/kg).", "study_duration": "Acute and chronic administration (specific duration not detailed).", "interactions": "Sildenafil (PDE5 inhibitor) showed dose-dependent interactions with L-DOPA.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:27.232168+00:00"}
{"study_id": 47446, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the anti-colorectal cancer properties of a novel niosome formulation (CG-Nio-CGLD) containing cyclo-Gly-L-DOPA.", "results_summary": "The study found that CG-Nio-CGLD demonstrated significant anti-cancer effects, including increased apoptosis-related gene expression (PP53, cas3, cas8) and reduced BCL2 and survivin levels, with minimal cytotoxicity to normal cells.", "population_specificity": "Colorectal cancer cell lines (CL40) and normal cell lines (CCD 841 CoN).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:27.331988+00:00"}
{"study_id": 47445, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate and compare the neuroprotective effects of L-Dopa-modified zinc nanoparticles (ZnNPs) in a 6-OHDA-induced Parkinson's disease rat model.", "results_summary": "L-Dopa-modified ZnNPs increased glutamate transporter activity, improved neuronal cell vitality, and enhanced behavioral performance, suggesting potential for neurotoxicity prevention and PD therapy.", "population_specificity": "6-OHDA-induced Parkinson's disease rat model", "effective_dosage": "5 mg/kg, 10 mg/kg, and 20 mg/kg L-Dopa; 20 mg/kg, 40 mg/kg ZnNPs; 30 mg/kg ZnNPs + L-Dopa; 60 mg/kg ZnNPs + L-Dopa", "study_duration": "14 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:27.885510+00:00"}
{"study_id": 47447, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of 7,8-DHF and DHF-ME in reducing L-DOPA-induced dyskinesia (LID) and correcting long-term signaling adaptations in a Parkinson's disease model.", "results_summary": "The study found that intranasal delivery of 7,8-DHF via liposomal formulation reduced LID in a hemiparkinsonian mice model and corrected signaling adaptations involving \u0394FosB and \u03b1 Synuclein in dopamine-depleted brains.", "population_specificity": "Hemiparkinsonian mice chronically administered L-DOPA.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:30.208958+00:00"}
{"study_id": 47449, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of post-synaptic serotonin receptor 5-HT4 in L-DOPA-induced dyskinesia and whether its modulation could reduce dyskinesia without compromising L-DOPA's motor benefits.", "results_summary": "The study found that RS 67333, a 5-HT4 receptor partial agonist, reduced L-DOPA-induced dyskinesia while preserving L-DOPA's pro-kinetic effects. It also enhanced cAMP-PKA pathway activation in striatopallidal medium spiny neurons, suggesting a potential therapeutic approach for dyskinesia.", "population_specificity": "Unilateral 6-OHDA mouse model of Parkinson's disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:34.237825+00:00"}
{"study_id": 47448, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if biphenyl-indanone A (BINA), a selective mGlu2 positive allosteric modulator, could alleviate parkinsonism either alone or in combination with a low dose of L-DOPA.", "results_summary": "BINA at 1 and 10 mg/kg significantly reduced parkinsonism severity (~22% and ~47%, respectively) when administered alone, comparable to a high L-DOPA dose. When combined with a low L-DOPA dose, BINA further reduced parkinsonism (~38% and ~53%) and also decreased dyskinesia (~94%) and psychosis-like behaviors (~92%).", "population_specificity": "MPTP-lesioned marmosets (a primate model of parkinsonism).", "effective_dosage": "BINA (0.1, 1, 10 mg/kg); L-DOPA/benserazide (15/3.75 mg/kg or 7.5/1.875 mg/kg).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:34.357637+00:00"}
{"study_id": 47450, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review the pharmacokinetic and pharmacodynamic limitations of L-DOPA and assess how current continuous dopaminergic delivery therapies address these issues.", "results_summary": "The study identified multiple Pk/Pd limitations of L-DOPA, including restricted absorption, peripheral distribution, short half-life, and pulsatile receptor stimulation, and found that current treatments only slightly ameliorate these problems.", "population_specificity": "Not specified (literature review of existing studies).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:34.358338+00:00"}
{"study_id": 47452, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether L-DOPA treatment affects neuroinflammation, A\u03b2 pathology, and tau phosphorylation in a mouse model of Alzheimer's disease.", "results_summary": "L-DOPA administration significantly reduced microgliosis, astrogliosis, and A\u03b2 plaque number by upregulating NEP and ADAM17 levels, but it did not alter tau hyperphosphorylation or tau kinase levels in 5xFAD mice.", "population_specificity": "5xFAD mice (a model of Alzheimer's disease)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:34.712213+00:00"}
{"study_id": 47451, "supplement_id": 1268, "safety_score": "60", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to assess the relationship between dopamine lesion, gait disturbances, and the potential reversal of these deficits with L-DOPA in a rat model of Parkinson's Disease.", "results_summary": "The study found that L-DOPA did not reverse lesion-induced gait impairments but induced abnormal involuntary movements (AIMs) at higher doses. Post-mortem analysis revealed striatal dopamine and norepinephrine loss, with prefrontal cortex norepinephrine reduction potentially contributing to gait alterations.", "population_specificity": "Sprague-Dawley rats (N = 25, 14 males, 11 females) with unilateral medial forebrain bundle dopamine lesions.", "effective_dosage": "0, 3, or 6 mg/kg (subcutaneous)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:35.727396+00:00"}
{"study_id": 47453, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether L-DOPA alleviates global cerebral ischemia-reperfusion (GCI/R)-induced cell death by enhancing mitochondrial quality in hippocampal neurons.", "results_summary": "L-DOPA stabilized mitochondrial membrane potential and ultrastructure, increased dopamine levels, decreased succinic acid, and stabilized Ca2+ levels in the hippocampus, suggesting improved mitochondrial function. Dopamine also inhibited mitoROS production and facilitated TCA cycle function, demonstrating neuroprotective effects against GCI/R injury.", "population_specificity": "GCI/R rats and isolated mouse hippocampal neurons (HT22) and primary rat hippocampal neurons.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:35.784897+00:00"}
{"study_id": 47454, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify the striatal cell populations and molecular mechanisms underlying L-Dopa-induced dyskinesia (LID) in Parkinson's disease.", "results_summary": "The study found that a subset of D1 receptor-expressing medium spiny neurons (D1-MSNs) showed transcriptional changes linked to LID, with repeated L-Dopa exposure inducing synaptic remodeling and activin signaling, which may play a key role in LID development. Pharmacological inhibition of activin signaling impaired LID progression.", "population_specificity": "Male hemiparkinsonian mice", "effective_dosage": "Not specified", "study_duration": "1, 5, or 10 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:36.269010+00:00"}
{"study_id": 47455, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to develop a more efficient method for synthesizing poly(levodopa) nanoparticles (P(l-DOPA) NPs) and evaluate their photothermal properties and efficacy in tumor therapy.", "results_summary": "P(l-DOPA) NPs were successfully synthesized using organic quaternary ammonium in hot water, demonstrating superior photothermal properties compared to polydopamine nanoparticles (PDA NPs). These NPs showed better efficacy in photothermal tumor therapy.", "population_specificity": "Not specified (in vitro or preclinical study implied).", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:38.142584+00:00"}
{"study_id": 47459, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to characterize the vibrational spectra and conformational behavior of L-Dopa to support future spectroscopic studies of its deuterated analogs.", "results_summary": "The study obtained high-quality Raman and ROA spectra of L-Dopa under specific conditions, identified its intrinsic flexibility with multiple conformations, and demonstrated that explicit solvation improved spectral simulation accuracy.", "population_specificity": "Not applicable (in vitro study)", "effective_dosage": "100 mg/ml (high concentration, low pH conditions)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:42.201549+00:00"}
{"study_id": 47457, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the L-dopa content, antioxidant properties, and anti-inflammatory potential of Mucuna laticifera seeds.", "results_summary": "The study found exceptionally high L-dopa content (174.3 mg/g) in M. laticifera seeds, along with robust antioxidant and anti-inflammatory effects, including reduced paw swelling and downregulation of inflammation-related genes in a rat model.", "population_specificity": "Carrageenan-induced inflammatory rat model.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:42.605070+00:00"}
{"study_id": 47456, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether co-treatment of ACE inhibitors (perindopril, captopril, enalapril) with L-dopa could reduce L-dopa-induced dyskinesia in a mouse model of Parkinson's disease.", "results_summary": "Co-treatment of ACE inhibitors with L-dopa significantly decreased LID development in 6-OHDA-lesioned mice and reduced astrocyte and microglial transcripts associated with inflammation in the striatum.", "population_specificity": "6-hydroxydopamine (6-OHDA)-lesioned mouse model of Parkinson's disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "ACE inhibitors (perindopril, captopril, enalapril)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:42.871059+00:00"}
{"study_id": 47460, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to identify and assess the efficacy of repurposed drugs (lorcaserin, acamprosate, ganaxolone) for treating L-DOPA-induced dyskinesia (LID) in Parkinson's disease.", "results_summary": "Lorcaserin reduced rotational asymmetry by 58% in rodents and LID by 82% in macaques, but increased parkinsonian disability. Acamprosate and ganaxolone showed no efficacy.", "population_specificity": "Rodents and MPTP-lesioned dyskinetic macaques.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:43.636544+00:00"}
{"study_id": 47458, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine whether 4'-F-CBD and HU-910, alone or in combination with other compounds, could mitigate L-DOPA-induced dyskinesia (LID) and associated striatal inflammatory and glutamatergic disturbances.", "results_summary": "The study found that 4'-F-CBD combined with CPZ reduced LID and normalized glutamatergic synapse markers, while HU-910 and other CB2 agonists were ineffective. Both combination treatments reduced neuroinflammation, but this alone did not prevent LID.", "population_specificity": "C57BL/6 mice with unilateral striatal lesions induced by 6-OHDA, rendered hemiparkinsonian.", "effective_dosage": "Not specified", "study_duration": "3-day treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:44.119792+00:00"}
{"study_id": 47461, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether suppressing corticostriatal glutamate inputs could mitigate L-dopa-induced dyskinesia (LID) in Parkinson's disease.", "results_summary": "The study found that suppressing glutamate inputs via NMDA antagonist (amantadine), optogenetic inactivation, or enhancing glutamate uptake (LDN 212320) reduced abnormal involuntary movements (AIMs) and striatal phospho-ERK1/2 and phospho-NR2B levels in L-dopa-treated mice.", "population_specificity": "6-OHDA-lesioned mice (animal model of Parkinson's disease).", "effective_dosage": "L-dopa (10 mg/kg, i.p., daily).", "study_duration": "2 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:45.527130+00:00"}
{"study_id": 47462, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine how GPR143, a receptor for L-DOPA, influences DRD2-mediated side effects of antipsychotics like haloperidol.", "results_summary": "The study found that GPR143 enhances DRD2-mediated side effects (e.g., catalepsy) of haloperidol, and reducing L-DOPA release or GPR143-DRD2 interactions suppressed these effects. GPR143 also increased DRD2 surface expression in cells.", "population_specificity": "Male Gpr143 gene-deficient mice and cholinergic interneuron-specific Gpr143-deficient mice.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Haloperidol (antipsychotic)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:45.578311+00:00"}
{"study_id": 47463, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the anti-dyskinetic effects of cholecalciferol (VD3) and its mechanisms in L-Dopa-induced dyskinesia (LID) in a Parkinson's disease model.", "results_summary": "VD3 significantly reduced abnormal involuntary movements (AIMs) by 32.7% on days 11 and 14, inhibited oxidative stress, inflammation, and microglial activation, but did not alter dopamine metabolic enzymes (TH and MAO-B).", "population_specificity": "Parkinsonian (6-OHDA-lesioned) mice.", "effective_dosage": "VD3 (30 mg/kg) or Amantadine (40 mg/kg).", "study_duration": "14 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:46.274346+00:00"}
{"study_id": 47464, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to assess the therapeutic effects of dual dopaminergic modulation (DDM) with L-DOPA and chlorpromazine (CPZ) in patients with idiopathic cervical dystonia (CD) who responded poorly to botulinum toxin treatment.", "results_summary": "The study found that combining L-DOPA with CPZ significantly reduced both motor symptoms and pain in CD patients, while neither L-DOPA nor CPZ alone showed improvement. The effects were dose-dependent.", "population_specificity": "21 patients with idiopathic cervical dystonia (CD) resistant to botulinum toxin treatment.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:50.914869+00:00"}
{"study_id": 47466, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the relationship between L-Dopa decarboxylase (DDC) expression and oxidative stress in human neural and non-neural cells.", "results_summary": "The study found that DDC expression remained stable or increased under oxidative stress induced by H2O2, despite RNA degradation and increased cytotoxicity. DDC silencing worsened H2O2-induced cytotoxicity, suggesting DDC's role in oxidative stress mechanisms.", "population_specificity": "Human neural and non-neural cells (in vitro study).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:51.366342+00:00"}
{"study_id": 47468, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to review therapeutic strategies for managing L-DOPA-induced dyskinesias (LIDs) in Parkinson's disease, focusing on glutamatergic dysregulation and phosphodiesterase inhibition.", "results_summary": "The study highlights that glutamatergic dysregulation in striatal projection neurons contributes to LIDs, with antiglutamatergic agents like amantadine showing promise, though novel therapies targeting phosphodiesterases are needed for improved outcomes.", "population_specificity": "Patients with advanced Parkinson's disease experiencing L-DOPA-induced dyskinesias.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:51.547002+00:00"}
{"study_id": 47465, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of low-dose L-Dopa on motor and vocal tics, as well as obsessive-compulsive disorder (OCD), in Gilles de la Tourette syndrome (GTS) patients previously treated with dopamine receptor antagonists.", "results_summary": "L-Dopa treatment led to greater improvement in motor tics but not vocal tics or OCD. Patients with prior dopamine blocker use showed more severe vocal tics and OCD, which persisted, while L-Dopa improved motor tic symptoms.", "population_specificity": "226 male GTS patients aged 5-14 years, with a subset of 110 patients and 26 normal participants assessed for saccade performance.", "effective_dosage": "Low-dose L-Dopa (specific amount not stated).", "study_duration": "Duration not explicitly stated.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:52.073752+00:00"}
{"study_id": 47470, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to develop an efficient biomimetic method for producing L-DOPA using a nanozyme that mimics tyrosine hydroxylase.", "results_summary": "The study demonstrated that the developed nanozyme effectively catalyzed the hydroxylation of tyrosine to L-DOPA, achieving a titer of 1.2 mM, with good reusability and enzyme kinetics comparable to tyrosine hydroxylase.", "population_specificity": "Not specified (in vitro study)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:53.103247+00:00"}
{"study_id": 47471, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine if neuro-inflammation, specifically the ratio of striatal M1 to M2 microglia, contributes to L-Dopa-induced dyskinesias and whether anti-inflammatories can mitigate these effects.", "results_summary": "The study found that L-Dopa-induced dyskinesias are strongly correlated with an increased M1/M2 microglia ratio, which anti-inflammatories (minocycline/indomethacin) reduced, thereby decreasing dyskinesia severity. Non-dyskinetic mice showed no increase in this ratio compared to untreated PD mice.", "population_specificity": "6-OHDA lesioned mice (Parkinson's disease model)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:54.480150+00:00"}
{"study_id": 47469, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to identify a valid index of L-DOPA-induced dyskinesia (LID) in dopamine-depleted dopamine-transporter KO (DDD) mice to screen compounds for Parkinson's disease.", "results_summary": "The study found that oral stereotypies were sensitized to L-DOPA in both open field and circular maze tests and responded to D1 receptor agonists and amantadine, suggesting they should be used as an index of LID in screening compounds for PD. Vertical counts and climbing were specific to the open field test.", "population_specificity": "Dopamine-depleted dopamine-transporter KO (DDD) mice.", "effective_dosage": "5 mg/kg SKF81297; 5 and 10 mg/kg MLM55-38; 45 mg/kg amantadine.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:54.528670+00:00"}
{"study_id": 47472, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine if paracetamol and its metabolite NAPQI could inhibit enzymes that metabolize dopamine and/or L-Dopa, potentially extending the therapeutic window of L-Dopa treatment for Parkinson's disease.", "results_summary": "The study predicted that paracetamol and NAPQI may inhibit the metabolism of L-Dopa and dopamine, thereby extending the duration of L-Dopa treatments, without inhibiting natural dopamine production. Benchmark calculations supported the accuracy of the computational methods used.", "population_specificity": "Not specified (computational study, no human or animal subjects).", "effective_dosage": "Not available", "study_duration": "Not applicable (computational study)", "interactions": "Paracetamol and NAPQI (potential enzyme inhibition)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:55.823202+00:00"}
{"study_id": 47473, "supplement_id": 1268, "safety_score": "40", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to assess the functional consequences of long-term L-DOPA exposure on cognitive and motor function in a rodent model of Parkinson's disease.", "results_summary": "Chronic L-DOPA exposure impaired motor and cognitive function in the absence of the drug, particularly in rats that developed dyskinesias (LIDs). Non-dyskinetic rats did not show these impairments.", "population_specificity": "Hemi-parkinsonian rats and intact rats.", "effective_dosage": "Not specified", "study_duration": "Chronic exposure (duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:58.591734+00:00"}
{"study_id": 47475, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to reflect on the historical development and therapeutic potential of L-DOPA for Parkinson's disease (PD) and discuss its clinical applications and modifications.", "results_summary": "The abstract highlights that L-DOPA successfully antagonized dopamine depletion symptoms, resembling PD, and became a cornerstone of PD therapy from the 1970s onward. It also notes the development of various administration methods and combination therapies for PD patients.", "population_specificity": "Parkinson's disease patients (general, not specified further).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:20:59.633347+00:00"}
{"study_id": 47474, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether human equivalent doses of L-DOPA/Carbidopa administered during the postnatal critical period could rescue visual function and retinal morphology in OCA1 mice.", "results_summary": "Higher doses of L-DOPA/Carbidopa diminished or eliminated impaired retinal morphology, decreased retinal function, and lower visual acuity in OCA1 mice, suggesting rescue via PEDF upregulation and modulation of retinal synaptogenesis.", "population_specificity": "OCA C57BL/6\u00a0J-c2J OCA1 mice (albinism model)", "effective_dosage": "3 different doses (specific amounts not stated)", "study_duration": "28-day course (from 15 to 43 days postnatal age)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:00.660788+00:00"}
{"study_id": 47476, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether activation of striatal mGlu2/3 receptors using LY354740 could attenuate L-DOPA-induced dyskinesia (LID) in parkinsonism rats and improve functional outcomes.", "results_summary": "LY354740 significantly reduced dyskinesia expression in established LID rats and attenuated LID development in parkinsonism rats, with an inverted-U dose-response curve. It also inhibited abnormal molecular changes (p-Fyn/p-NMDA/p-ERK1/2/p-HistoneH3/\u0394FosB) linked to LID.", "population_specificity": "Parkinsonism rat models and stable LID rats.", "effective_dosage": "12 mg/kg (i.p.), 20 nmoL or 40 nmoL (intrastriatal injection).", "study_duration": "4 days of continuous injection.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:02.062785+00:00"}
{"study_id": 47477, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effects of NLX-112, a 5-HT1A agonist, on L-DOPA-induced dyskinesia (LID) and brain activation patterns in hemiparkinsonian rats.", "results_summary": "L-DOPA caused hypermetabolism in motor areas and hypometabolism in cortical regions, with additional effects in HPK-LID rats. NLX-112 attenuated L-DOPA-induced metabolic changes and partially restored altered neural connectivity, suggesting potential benefits against LID and non-motor symptoms.", "population_specificity": "Hemiparkinsonian rats with unilateral nigrostriatal 6-OHDA lesions, divided into LID and non-LID groups.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:02.064186+00:00"}
{"study_id": 47478, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to identify metabolic pathways in coffee plants that produce L-DOPA and assess its potential as a natural source for medicinal use.", "results_summary": "The study identified active metabolic pathways in coffee plants producing L-DOPA, a compound used to treat Parkinson's disease, and predicted other medicinal compounds. LC-MS/MS confirmed L-DOPA presence in coffee plant tissues.", "population_specificity": "Coffea arabica and Coffea canephora (coffee plants)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:02.122339+00:00"}
{"study_id": 47480, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the mechanisms behind statins' anti-dyskinetic effects on L-DOPA-induced dyskinesia (LID) and explore potential interactions between angiotensin/AT1, cholesterol, and ROCK pathways.", "results_summary": "The study found that statins, candesartan, and fasudil reduced cholesterol, ROCK, and IL-1\u03b2 levels in dyskinetic rats, suggesting these pathways contribute to LID. Angiotensin II increased cholesterol biosynthesis in neurons and altered cholesterol metabolism in astrocytes, indicating a potential transfer mechanism.", "population_specificity": "Dyskinetic rats (animal model)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:04.398054+00:00"}
{"study_id": 47481, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of TrkB receptor in L-DOPA-induced dyskinesia (LID) and determine whether BDNF/TrkB signaling could mitigate LID severity.", "results_summary": "Chronic L-DOPA treatment increased TrkB receptor levels and activation in dopamine-depleted striatum, with TrkB deletion in D1 receptor-expressing neurons worsening axial LID. The study suggests BDNF/TrkB signaling may protect against LID development.", "population_specificity": "Hemiparkinsonian mice with unilateral dopamine neuron lesions.", "effective_dosage": "Not specified", "study_duration": "10 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:06.680697+00:00"}
{"study_id": 47482, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to develop a novel amperometric biosensor for rapid and accurate detection of L-Dopa levels in human plasma to optimize dosing and improve therapeutic outcomes in Parkinson's disease.", "results_summary": "The study successfully developed a biosensor with high sensitivity, a wide linear range, and a low detection limit (0.84 \u03bcM) suitable for monitoring L-Dopa within its therapeutic window. The device showed minimal interference from endogenous compounds and was effectively applied to human plasma with good recoveries.", "population_specificity": "Drug-treated patients (implied, not explicitly stated).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "Ascorbic acid exhibited inhibitory behavior and was excluded from the enzymatic layer using a Nafion membrane.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:08.049853+00:00"}
{"study_id": 47483, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of zonisamide (ZNS) on L-DOPA-induced dyskinesia (LID) in Parkinson's disease model mice.", "results_summary": "Chronic ZNS treatment with L-DOPA delayed the peak of LID and reduced its severity before the peak but increased the duration of LID in a dose-dependent manner compared to L-DOPA alone. Acute ZNS treatment had no observable behavioral effects on LID.", "population_specificity": "Parkinson's disease model mice", "effective_dosage": "Not specified", "study_duration": "Chronic treatment (duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:08.975551+00:00"}
{"study_id": 47487, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine how L-DOPA affects breathing and respiratory response to hypercapnia in a reserpine-induced model of Parkinson's disease.", "results_summary": "L-DOPA reversed reduced ventilation caused by reserpine, demonstrating a stimulatory effect on breathing and restoring normal respiratory activity. The study found significant differences in respiratory rate and minute ventilation between sham rats and the reserpine-treated group, which were mitigated by L-DOPA.", "population_specificity": "Reserpine-treated rats (animal model of Parkinson's disease and parkinsonism).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:12.155178+00:00"}
{"study_id": 47486, "supplement_id": 1268, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of KW-6356 combined with L-DOPA on anti-parkinsonian activity and dyskinesia in MPTP-treated marmosets.", "results_summary": "KW-6356 enhanced the anti-parkinsonian effects of L-DOPA across various doses without increasing dyskinesia, though chronic co-administration slightly elevated dyskinesia at low L-DOPA doses. The combined therapy showed lower dyskinesia risk compared to high-dose L-DOPA alone.", "population_specificity": "MPTP-treated common marmosets primed with L-DOPA to exhibit dyskinesia.", "effective_dosage": "L-DOPA (1.25-10 mg/kg), KW-6356 (1 mg/kg)", "study_duration": "21 days (chronic co-administration)", "interactions": "KW-6356 (adenosine A2A receptor antagonist/inverse agonist)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:12.589449+00:00"}
{"study_id": 47485, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of L-DOPA alone versus L-DOPA combined with ropinirole on dyskinesia severity and duration in Parkinson's disease patients.", "results_summary": "The study found that L-DOPA alone caused higher peak dyskinesia severity, while the L-DOPA-ropinirole combination resulted in longer-lasting but less severe dyskinesia. Accelerometer data validated the clinical ratings, suggesting a potential for machine-learning-based dyskinesia assessment.", "population_specificity": "25 Parkinson's disease patients with a history of dyskinesias.", "effective_dosage": "150% of usual morning L-DOPA dose, with or without equipotent ropinirole.", "study_duration": "Single-dose challenges with assessments up to 270 minutes post-administration.", "interactions": "Ropinirole (a dopamine agonist) was studied in combination with L-DOPA.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:12.638518+00:00"}
{"study_id": 47489, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers sought to determine how DA depletion and L-DOPA treatment affect DAT and SERT transcriptional, translational, and functional DA uptake in a hemi-parkinsonian rat model.", "results_summary": "The study found that nigrostriatal DA loss severely reduced DAT mRNA and protein expression with minimal changes in SERT. L-DOPA treatment increased striatal SERT:DAT protein ratios and DA uptake via SERT when DAT was depleted.", "population_specificity": "6-hydroxydopamine-lesioned hemi-parkinsonian rats", "effective_dosage": "6 mg/kg daily", "study_duration": "2 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:15.925281+00:00"}
{"study_id": 47488, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether the nitric oxide synthase inhibitor 7-nitroindazole (7-NI) could reduce L-DOPA-induced dyskinesias (LIDs) in a non-human primate model of Parkinson's disease.", "results_summary": "The study found that 7-NI significantly reduced LIDs in MPTP-treated monkeys without diminishing the anti-Parkinsonian effects of L-DOPA. The improvement in LID intensity and duration was significant while maintaining L-DOPA's therapeutic benefits.", "population_specificity": "Six Parkinsonian macaques chronically intoxicated with MPTP.", "effective_dosage": "Single dose of 7-NI administered 45 min before each L-DOPA treatment (specific dosage not provided).", "study_duration": "3-4 months of daily L-DOPA treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:16.111916+00:00"}
{"study_id": 47490, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the cumulative effects of chronic L-dopa administration and the potential mechanism of eltoprazine's amelioration of dyskinesia at the electrophysiological level in rats.", "results_summary": "The study found exaggerated gamma oscillations in dyskinetic states, with distinct regional features, and demonstrated that eltoprazine reduced gamma oscillations and theta-gamma phase-amplitude coupling to alleviate dyskinesia. Enhanced gamma-band coherence and functional connectivity were also observed following L-dopa administration.", "population_specificity": "Rats with Parkinson's disease model", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:16.770240+00:00"}
{"study_id": 47493, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of amantadine on L-Dopa-induced dyskinesia (LID) and motor fluctuations in a hemiparkinsonian rat model.", "results_summary": "L-Dopa-induced abnormal movements were initially reduced by amantadine, but this effect diminished with repetitive treatment. However, amantadine extended L-Dopa \"on\" time after repeated use, though it did not prevent the priming effects of L-Dopa.", "population_specificity": "Hemiparkinsonian rats induced by 6-hydroxydopamine injections.", "effective_dosage": "Not specified in the abstract.", "study_duration": "31 days (with varying treatment schedules across groups).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:21.090611+00:00"}
{"study_id": 47491, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to test whether hydrogen gas (H2) inhalation could reduce L-DOPA-induced dyskinesia in a preclinical Parkinson's disease model.", "results_summary": "H2 inhalation attenuated L-DOPA-induced dyskinesia without impairing locomotor improvement, reduced activated microglia and pro-inflammatory cytokines, and showed correlations between abnormal involuntary movements and cytokine levels.", "population_specificity": "Rats with 6-hydroxydopamine lesions of dopaminergic neurons (preclinical Parkinson's disease model).", "effective_dosage": "2% H2 gas mixture for 1 hour before L-DOPA injection.", "study_duration": "15 days of chronic L-DOPA treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:21.323496+00:00"}
{"study_id": 47492, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether chronic administration of immepip (an H3R agonist) could reduce L-Dopa-induced dyskinesias (LIDs) and modulate glutamate/GABA levels and D1R/H3R mRNA expression in a rat model of Parkinson's disease.", "results_summary": "Chronic immepip administration reduced LIDs, prevented or diminished L-Dopa-induced increases in GABA and glutamate levels in the cortex and striatum, and prevented the decrease in D1R mRNA in the ipsilateral striatum. L-Dopa alone increased GABA and glutamate in the cortex but had no significant effect on striatal glutamate.", "population_specificity": "Unilaterally 6-hydroxydopamine-lesioned rats (Parkinson's disease model).", "effective_dosage": "Not specified in the abstract.", "study_duration": "21 days of L-Dopa administration.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:22.047716+00:00"}
{"study_id": 47495, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate how L-DOPA-induced dyskinesia affects the dynamics of NG2-glia in the striatum and whether doxycycline therapy can reverse these changes.", "results_summary": "The study found that L-DOPA reduced striatal NG2-glia density and induced an activated phenotype, while doxycycline therapy restored NG2-glia density and protein to a non-activated state.", "population_specificity": "Animal model (specific species not mentioned in the abstract).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:23.528031+00:00"}
{"study_id": 47494, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of striatal D2 receptor-positive neurons and downstream GPe neurons in L-Dopa-induced dyskinesia (LID) in a rat model.", "results_summary": "The study found that overinhibition of striatal D2R+ neurons and hyperactivity of downstream GPe neurons contributed to dyskinesia in LID rats. Optogenetic activation of these neurons or their projections suppressed dyskinetic behaviors.", "population_specificity": "Rat model of L-Dopa-induced dyskinesia (LID)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:23.594242+00:00"}
{"study_id": 47479, "supplement_id": 1268, "safety_score": "60", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of L-DOPA and ropinirole, alone or in combination, on glial and microvascular reactivity in the striatum of rats with Parkinson's-like lesions.", "results_summary": "L-DOPA alone or combined with ropinirole induced moderate-severe dyskinesia, while ropinirole alone had negligible dyskinetic effects. L-DOPA caused significant perivascular microglial and astroglial reactivity, increased microvessel density, and albumin extravasation, whereas these effects were absent with L-DOPA-ropinirole or ropinirole alone.", "population_specificity": "Rats with unilateral 6-hydroxydopamine lesions (Parkinson's disease model).", "effective_dosage": "L-DOPA (6 mg/kg), L-DOPA (3 mg/kg) plus ropinirole (0.5 mg/kg), or ropinirole alone.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:24.404172+00:00"}
{"study_id": 47496, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the durability and pharmacological mechanisms of vortioxetine's anti-dyskinetic effects in L-DOPA-induced dyskinesia (LID) in Parkinson's Disease.", "results_summary": "Vortioxetine consistently and dose-dependently reduced LID, with 5-HT1A and 5-HT1B receptors each partially reversing its effects, suggesting broad 5-HT actions may offer durable responses without significant side effects.", "population_specificity": "Hemiparkinsonian rats", "effective_dosage": "Not specified", "study_duration": "Sub-chronic (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:24.443262+00:00"}
{"study_id": 47497, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of L-Dopa and BM-MSCs-derived exosomes on neurogenic repair and functional restoration in a Parkinson's disease rat model.", "results_summary": "L-Dopa improved motor function, histopathology, and levels of \u03b1-synuclein, PARKIN, and DJ-1 compared to untreated PD rats, but MSC-derived exosomes showed greater suppression of neurodegenerative markers and additional improvements in microRNA-34b and circRNA.2837.", "population_specificity": "Male albino rats induced with Parkinson's disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:28.777999+00:00"}
{"study_id": 47498, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to describe the development of an enzymatic synthesis method for L-DOPA using bacterial L-tyrosine phenol-lyase (Tpl) and explore its production conditions.", "results_summary": "The study detailed the screening of bacterial strains, culture conditions, enzyme properties, reaction mechanisms, and optimized conditions for L-DOPA production. It also highlighted molecular breeding of Tpl-overproducing strains through mutations in the TyrR protein.", "population_specificity": "Not specified (focus on bacterial strains and enzymatic processes).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:28.891185+00:00"}
{"study_id": 47499, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the efficacy of PT320 in mitigating L-DOPA-induced dyskinetic behaviors and its effects on dopaminergic transmission in a progressive Parkinson's disease MitoPark mouse model.", "results_summary": "Early administration of PT320 significantly reduced L-DOPA-induced abnormal involuntary movements, particularly excessive standing and abnormal paw movements, but did not affect locomotor hyperactivity. Late PT320 administration showed no attenuation of dyskinesia. Early PT320 treatment also increased tonic and phasic dopamine release in striatal slices.", "population_specificity": "MitoPark mice (a progressive Parkinson's disease mouse model) at 5 or 17 weeks old.", "effective_dosage": "Clinically translatable biweekly PT320 dose (specific amount not stated).", "study_duration": "Early treatment group: up to 22 weeks; late treatment group: up to 29 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:31.240954+00:00"}
{"study_id": 47502, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the effect and mechanism of L-DOPA in treating age-related macular degeneration (AMD), specifically focusing on its cytoprotective effects and the role of circ-SGMS1.", "results_summary": "L-DOPA (20 \u03bcM) showed the best therapeutic effect in a wet AMD cell model, reversing CoCl2-induced damage. Overexpression of circ-SGMS1, a differentially expressed circRNA, alleviated AMD by inhibiting HIF-1a and THBS1 expression.", "population_specificity": "ARPE-19 cells (a human retinal pigment epithelial cell line) treated with CoCl2 to model wet AMD.", "effective_dosage": "20 \u03bcM L-DOPA", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:32.522075+00:00"}
{"study_id": 47503, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to characterize the relationship between L-DOPA-induced dyskinesia (LID) and Parkinson's disease-associated psychosis (PDAP) in a rat model and test Vilazodone's potential to mitigate these effects.", "results_summary": "Chronic L-DOPA induced moderate abnormal involuntary movements (AIMs), with more severe AIMs correlating with sensorimotor gating dysfunction. Vilazodone dose-dependently reduced L-DOPA-induced AIMs without impairing L-DOPA efficacy but had limited effects on PPI dysfunction.", "population_specificity": "Bilateral medial forebrain bundle 6-OHDA lesion rat model.", "effective_dosage": "Not specified", "study_duration": "Chronic (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:32.853632+00:00"}
{"study_id": 47504, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine if doxycycline could alleviate L-DOPA-induced dyskinesia (LID) in Parkinson's disease by targeting neuroinflammation.", "results_summary": "Doxycycline significantly reduced LID in mice with moderate and intermediate dopaminergic lesions without impairing locomotor activity. The anti-inflammatory effects of doxycycline, including reduced Fos-B, COX-2, PGE2, TNF-\u03b1, and IL-1\u03b2 levels, were associated with LID attenuation.", "population_specificity": "C57BL/6 mice with moderate or intermediate mesostriatal dopaminergic lesions induced by 6-OHDA.", "effective_dosage": "20 mg kg-1 and 40 mg kg-1, administered subcutaneously before L-DOPA.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:33.764900+00:00"}
{"study_id": 47506, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers sought to determine whether cortical sensorimotor inhibition (SAI) related to cholinergic and GABA-ergic activities is impaired in Parkinson's disease patients with L-dopa-unresponsive freezing of gait (ONOFF-FOG).", "results_summary": "The study found that ONOFF-FOG patients showed significantly reduced SAI compared to controls and other PD groups, with dopaminergic therapy having no effect on this alteration. Reduced SAI was associated with severe FOG manifestations and impaired gait characteristics, suggesting dysfunction in thalamocortical cholinergic-GABAergic pathways.", "population_specificity": "28 PD patients with ONOFF-FOG, 15 PD patients with OFF-FOG, 25 PD patients without FOG, and 20 healthy controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:37.766542+00:00"}
{"study_id": 47505, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether selective mGlu2 positive allosteric modulation could alleviate parkinsonian disability as monotherapy or as an adjunct to a sub-optimal dose of L-DOPA.", "results_summary": "LY-487,379 (10 mg/kg) as monotherapy reduced global parkinsonism by 48% and increased on-time duration by 7-fold. When combined with a sub-optimal L-DOPA dose, it reduced parkinsonism by 44% and extended on-time by 2.5-fold.", "population_specificity": "MPTP-lesioned marmosets (a primate model of Parkinson's disease).", "effective_dosage": "LY-487,379 10 mg/kg (monotherapy and adjunct to sub-optimal L-DOPA).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:37.992595+00:00"}
{"study_id": 47508, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to develop an efficient multi-enzyme cascade pathway for synthesizing Danshensu (DSS) from L-DOPA.", "results_summary": "The study achieved a 98.3% yield of DSS from L-DOPA under optimal conditions, with a space-time yield of 6.61 g L-1 h-1. Elevated L-DOPA concentrations (100 mM) reduced DSS yield due to inhibited enzyme activity caused by NH4+ accumulation.", "population_specificity": "Not applicable (in vitro enzymatic study)", "effective_dosage": "20 mM and 40 mM L-DOPA concentrations tested", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:40.393066+00:00"}
{"study_id": 47507, "supplement_id": 1268, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to determine if AV-101 (a pro-drug of 7-Cl-KYNA) could reduce L-Dopa-induced dyskinesias (LID) in MPTP-lesioned monkeys while preserving L-Dopa's antiparkinsonian effects.", "results_summary": "AV-101 reduced LID significantly when combined with L-Dopa and maintained antiparkinsonian activity without causing non-motor adverse effects. The antidyskinetic effect of AV-101 was comparable to amantadine but with fewer side effects.", "population_specificity": "MPTP-lesioned monkeys (Parkinson's disease model).", "effective_dosage": "250 mg/kg and 450 mg/kg (acute study); 250 mg/kg b.i.d. (main study).", "study_duration": "4 consecutive days (main study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:41.046855+00:00"}
{"study_id": 47509, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether L-dopa modifies the beneficial effects of iTBS-\u03b3-tACS on motor cortex plasticity and GABA-A-ergic inhibition in Parkinson's disease patients.", "results_summary": "The study found that iTBS-\u03b3-tACS improved motor cortex plasticity and GABA-A-ergic transmission in PD patients, with similar effects observed both OFF and ON dopaminergic therapy. L-dopa did not influence the beneficial effects of \u03b3-tACS, suggesting a lack of interaction between the two at the motor cortex level.", "population_specificity": "Parkinson's disease patients (both OFF and ON dopaminergic therapy)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:41.068779+00:00"}
{"study_id": 47511, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the patterns of cortico-basal ganglia oscillations induced by selective D1 and D2 receptor agonists in a rat model of L-DOPA-induced dyskinesia (LID).", "results_summary": "The study found that D1 and D2 receptor agonists induced dyskinesia with distinct patterns of neuronal oscillations, with D1 agonists causing high gamma oscillations in most structures and D2 agonists inducing theta oscillations in specific regions. The D1 agonist also led to stronger functional connectivity between motor cortex and striatum.", "population_specificity": "Rat model of Parkinson's disease with L-DOPA-induced dyskinesia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:42.028698+00:00"}
{"study_id": 47500, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether pregnenolone could reduce L-DOPA-induced dyskinesias (LIDs) in a rat model of Parkinson's Disease without compromising L-DOPA's motor benefits.", "results_summary": "Pregnenolone dose-dependently reduced LIDs without affecting L-DOPA's motor improvements, mirrored by reductions in striatal markers of dyskinesias and BDNF levels. The effects were comparable to the 5AR inhibitor dutasteride, suggesting pregnenolone as a potential therapeutic target for LIDs.", "population_specificity": "6-OHDA-lesioned male rats (Parkinson's Disease model)", "effective_dosage": "6, 18, 36 mg/kg of pregnenolone", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:43.781070+00:00"}
{"study_id": 47484, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether L-Dopa could prevent temozolomide-induced cognitive impairments in mice, focusing on memory deficits and neuroinflammatory markers.", "results_summary": "L-Dopa administration (25 mg/kg and 75 mg/kg) normalized behavioral function, reduced hippocampal TNF-\u03b1 and BDNF mRNA expression levels, and prevented histological damage in mice treated with temozolomide, suggesting it mitigates cognitive deficits via antineuroinflammatory effects.", "population_specificity": "BALB/c mice subjected to temozolomide-induced cognitive impairment.", "effective_dosage": "25 mg/kg and 75 mg/kg L-Dopa, administered with benserazide.", "study_duration": "6 days of L-Dopa administration alongside 3 days of temozolomide.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:44.281824+00:00"}
{"study_id": 47513, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether dopamine, via L-DOPA administration, enhances neural representations of direction during spatial navigation in younger and older adults.", "results_summary": "L-DOPA improved classification of brain activation patterns associated with walking directions across all studied regions, indicating dopamine broadly enhances directional neural representations. Effects were observed in both age groups in the hippocampus but only in younger adults in the retrosplenial cortex.", "population_specificity": "43 younger and 37 older adults.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:45.863922+00:00"}
{"study_id": 47512, "supplement_id": 1268, "safety_score": "50", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine the role of D2 receptor (D2R) signaling in striatal medium spiny neurons (iMSNs) in levodopa-induced dyskinesia (LID) and its impact on motor impairments in Parkinson's disease.", "results_summary": "The study found that loss of dopamine-mediated inhibition in iMSNs intensifies LID and reprograms striatal gene expression, suggesting D2R signaling critically influences motor impairments in PD and its therapy.", "population_specificity": "6-hydroxydopamine model of Parkinson's disease (animal study).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:46.026589+00:00"}
{"study_id": 47516, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of serotonin receptor agonists (buspirone and zolmitriptan) compared to amantadine in reducing L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.", "results_summary": "The combination of buspirone and zolmitriptan effectively reduced abnormal involuntary movements (AIM scores) synergistically, showed superior performance to amantadine, and was safe without tolerance development.", "population_specificity": "Hemiparkinsonian 6-OHDA-lesioned rats chronically treated with L-DOPA.", "effective_dosage": "Not specified", "study_duration": "Sub-chronic administration (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:49.744068+00:00"}
{"study_id": 47514, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of desipramine, alone and combined with L-DOPA, on motor behavior and monoamine metabolism in a rat model of Parkinson's disease.", "results_summary": "Desipramine combined with L-DOPA increased contralateral rotations more than L-DOPA alone and elevated dopamine levels in several brain regions. The combined treatment also increased noradrenaline in the striatum, while L-DOPA alone reduced serotonin in the hippocampus.", "population_specificity": "Rats with unilateral 6-OHDA lesions (a Parkinson's disease model).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Chronic administration (exact duration not specified).", "interactions": "Desipramine + L-DOPA combination showed synergistic effects on motor behavior and monoamine levels.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:49.755751+00:00"}
{"study_id": 47515, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to develop a two-step bioprocess for converting L-DOPA into Salvianic acid A (SAA) using engineered E. coli cells.", "results_summary": "The study successfully converted 50 mM of L-DOPA into 48.3 mM of SAA with a 96.6% yield, demonstrating high production efficiency and environmental friendliness. The bioprocess showed promise for industrial SAA production.", "population_specificity": "Not applicable (in vitro study using engineered E. coli cells).", "effective_dosage": "50 mM of L-DOPA.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:50.102058+00:00"}
{"study_id": 47517, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether foliglurax, an mGlu4-PAM, could restore synaptic plasticity and reduce L-Dopa-induced dyskinesia in a Parkinson's disease model.", "results_summary": "Foliglurax, when co-administered with L-Dopa, restored dendritic spine density, rescued striatal bidirectional plasticity, and attenuated dyskinesia intensity in 6-OHDA-lesioned rats. The effects were dose-dependent.", "population_specificity": "6-OHDA-lesioned rats (a Parkinson's disease model).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:50.217018+00:00"}
{"study_id": 47518, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to develop an improved method for simple and rapid quantification of L-DOPA content in plant tissues using liquid chromatography-tandem mass spectrometry.", "results_summary": "The study found that the improved method allowed quantification of L-DOPA from small amounts of plant tissue (e.g., one cotyledon) without purification steps, detecting high endogenous levels in faba bean sprouts (~4,000 \u00b5g g-1 FW) and low levels in other plants like broccoli and radish sprouts.", "population_specificity": "Plant tissues (faba bean, broccoli, Japanese white radish, pea, and red cabbage sprouts).", "effective_dosage": "Not specified (endogenous levels measured).", "study_duration": "Not specified (single measurement).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:52.595821+00:00"}
{"study_id": 47519, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to determine how L-DOPA and dopamine interact with gold nanoparticles (AuNPs) during functionalization and assess their structural changes and oxidation products.", "results_summary": "The study found that the final form of catechol (L-DOPA or dopamine) on AuNPs depends on the molar ratio of Au used, with excess L-DOPA needed for fully reduced catechols, while excess Au promoted oxidation and cyclization into products like dopachrome, which had high affinity for AuNP binding.", "population_specificity": "Not applicable (in vitro study)", "effective_dosage": "Not specified (molar ratios discussed)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:52.623457+00:00"}
{"study_id": 47521, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to test the effect of continuous dopaminergic stimulation (CDS) on L-DOPA-induced dyskinesia (LID) and its mechanism involving the calcium signaling pathway.", "results_summary": "CDS reduced abnormal involuntary movement (AIM) scores, increased tyrosine hydroxylase (TH) expression in the substantia nigra, decreased nNOS and BAX/BCL2 ratio in the striatum, and inhibited L-DOPA-induced Ca2+ influx and synaptic overactivity. RGTB showed promise in simulating CDS to reduce LID risk.", "population_specificity": "6-OHDA-treated rats (a Parkinson's disease model).", "effective_dosage": "L-DOPA and rotigotine behenate (RGTB) administered, but exact dosages not specified.", "study_duration": "28 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:56.635544+00:00"}
{"study_id": 47520, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the effect of bitopertin, a GlyT1 inhibitor, on parkinsonism and dyskinesia when used alone or as an adjunct to L-DOPA in a rat model.", "results_summary": "Bitopertin reduced parkinsonism severity by 35% when used alone and enhanced L-DOPA's anti-parkinsonian effect by 36%. It also reduced dyskinesia by 27% acutely and attenuated dyskinesia development by 33% when started concurrently with L-DOPA.", "population_specificity": "6-OHDA-lesioned rats", "effective_dosage": "0.3 mg/kg (monotherapy), 3 mg/kg (adjunct to L-DOPA), 0.03 mg/kg (acute and chronic dyskinesia studies)", "study_duration": "4 weeks (chronic administration)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:56.664857+00:00"}
{"study_id": 192362, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine the role of one-carbon metabolism and homocysteine levels in Parkinson's disease (PD) and assess the potential benefits of B-vitamin supplementation, particularly for individuals on L-DOPA treatment.", "results_summary": "The study suggests that B-vitamin supplementation may benefit PD-affected individuals, especially those on L-DOPA, by improving methylation capacity and reducing oxidative stress, though the precise relationship remains unclear.", "population_specificity": "PD-affected individuals, particularly those on L-DOPA treatment.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:57.975969+00:00"}
{"study_id": 192360, "supplement_id": 1268, "safety_score": "70", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether L-Dopa supplementation could enhance the effects of cognitive training on spatial and verbal fluid intelligence in healthy older adults.", "results_summary": "The study found that L-Dopa supplementation resulted in less improvement in spatial intelligence compared to placebo, with no significant difference in verbal intelligence. Participants on L-Dopa also progressed slower through training and showed differential volumetric changes in the midbrain.", "population_specificity": "Healthy adults aged 65-75 with Mini-Mental State Examination scores >25 and no serious medical conditions.", "effective_dosage": "100/25 mg L-dopa/benserazide prior to each of twenty cognitive training sessions.", "study_duration": "Four weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:58.563159+00:00"}
{"study_id": 192359, "supplement_id": 1268, "safety_score": "65", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the relationship between L-Dopa metabolism, homocysteine levels, and the risk of non-motor symptoms in Parkinson's disease patients.", "results_summary": "Long-term L-Dopa/DDI use without COMT inhibitors or vitamin B supplementation was associated with elevated homocysteine levels and reduced vitamin B metabolites, increasing the risk of peripheral neuropathy and cognitive disturbances. The review suggests supplementing with vitamins B6 and B12 to mitigate these effects.", "population_specificity": "Parkinson's disease patients on long-term L-Dopa/DDI regimens, particularly those treated with L-Dopa/carbidopa intestinal gel (LCIG) infusion.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "COMT inhibitors and methyl group-donating vitamins (B6, B12) were noted to interact with L-Dopa metabolism.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:58.940726+00:00"}
{"study_id": 192364, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention L-Dopa or its effects.", "results_summary": "The abstract does not discuss L-Dopa or its effects.", "population_specificity": "Patients with hyperphenylalaninemia (HPA) detected through newborn screening for phenylketonuria (PKU).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:59.761237+00:00"}
{"study_id": 47522, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to develop a biomimetic system for efficient and specific production of L-DOPA from tyrosine, mimicking the natural enzyme tyrosine hydroxylase.", "results_summary": "The biomimetic system demonstrated high catalytic activity and regioselectivity, achieving a yield of 52.01%, a titer of 3.22 mM, and a productivity of 48,210.68 mg L-1 h-1 under optimized conditions. The system shared an analogous catalytic mechanism with tyrosine hydroxylase and formed FeIVO2+ as the major active species.", "population_specificity": "Not specified (in vitro study)", "effective_dosage": "6.4 mM tyrosine, 1.6 mM Fe2+, 1.92 mM EDTA, 150 mM H2O2, 35 mM ascorbic acid in 0.2 M glycine-HCl buffer at pH 4.5 and 60 \u00b0C", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:21:59.763403+00:00"}
{"study_id": 192363, "supplement_id": 1268, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to explore the implications of L-DOPA's success in Parkinson's disease for developing symptomatic therapeutic strategies for Alzheimer's disease.", "results_summary": "The study highlighted that L-DOPA combined with modulators of its metabolism significantly improved the prognosis and extended survival time in Parkinson's disease patients, suggesting a potential parallel approach for Alzheimer's disease by targeting cholinergic function and brain energy metabolism.", "population_specificity": "Parkinson's disease patients (implied, not explicitly studied in this abstract).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:01.289521+00:00"}
{"study_id": 192366, "supplement_id": 1268, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine the duration of L-Dopa monotherapy before supplementation is needed and compare its tolerability to dopamine agonists in Parkinson's disease patients.", "results_summary": "L-Dopa monotherapy lasted significantly longer (3.6 years) before requiring supplementation compared to dopamine agonists (2.3 years). Discontinuation rates due to side effects were much lower for L-Dopa (1%) than for dopamine agonists (20%).", "population_specificity": "345 Parkinson's disease patients (180 on L-Dopa, 165 on dopamine agonists).", "effective_dosage": "Not specified", "study_duration": "Up to 4 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:04.268800+00:00"}
{"study_id": 192365, "supplement_id": 1268, "safety_score": "80", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine whether amino acid supplementation in protein-restricted Parkinson's patients on L-Dopa therapy affects neurological control, insulin sensitivity, and oxidative stress.", "results_summary": "Amino acid supplementation did not negatively impact neurological outcomes or L-Dopa requirements but partially mitigated insulin resistance and oxidative stress compared to placebo.", "population_specificity": "Protein-restricted Parkinson's disease patients chronically treated with L-Dopa (n=14).", "effective_dosage": "Amino acid supplementation twice daily (specific dosage not provided).", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:04.445178+00:00"}
{"study_id": 192368, "supplement_id": 1268, "safety_score": "40", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to investigate the association between duodenal levodopa infusion, vitamin B(12) deficiency, and the development of polyneuropathy or Guillain-Barr\u00e9 syndrome in Parkinson's disease patients.", "results_summary": "The study found that duodenal levodopa infusion may lead to vitamin B(12) deficiency, resulting in axonal polyneuropathy in some Parkinson's disease patients. It also suggested potential mechanisms, including altered L-dopa metabolism and direct neurotoxicity at high doses, and recommended considering vitamin B(12) supplementation.", "population_specificity": "Parkinson's disease patients treated with continuous duodenal levodopa infusion.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:06.519458+00:00"}
{"study_id": 192369, "supplement_id": 1268, "safety_score": "60", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to investigate the long-term effects of L-Dopa/DDI formulations on homocysteine synthesis in Parkinson's disease patients and explore potential therapeutic strategies to mitigate these effects.", "results_summary": "The study found that long-term L-Dopa/DDI intake increases plasma homocysteine levels, potentially increasing vulnerability to non-motor symptoms. It suggested that homocysteine reduction could be achieved through vitamin supplementation or COMT inhibitor combination, and proposed homocysteine monitoring as a biomarker for detoxification potential.", "population_specificity": "Parkinson's disease patients", "effective_dosage": "Not specified", "study_duration": "Long-term (specific duration not mentioned)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:06.866485+00:00"}
{"study_id": 22902, "supplement_id": 1269, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether Magnesium L-threonate (MgT) supplementation improves sleep quality and daily function in adults with self-assessed sleep problems.", "results_summary": "MgT significantly improved deep sleep, REM sleep, light sleep time, and daytime activity and readiness compared to placebo. Subjective measures also showed improvements in mood, energy, alertness, and productivity.", "population_specificity": "35-55-year-olds with self-assessed sleep problems.", "effective_dosage": "1 g/day", "study_duration": "21 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:06.889960+00:00"}
{"study_id": 22901, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine if magnesium-L-threonate (MgT) could improve cognitive deficits in an Alzheimer's disease mouse model by enhancing adult hippocampal neurogenesis and to explore the underlying mechanisms.", "results_summary": "MgT treatment improved memory impairment in AD mice, increased newborn neuron markers (BrdU/doublecortin), and elevated doublecortin expression. These effects were linked to ERK/CREB activation and were reversed by an ERK inhibitor.", "population_specificity": "APPswe/PS1dE9 transgenic mice (Alzheimer's disease model).", "effective_dosage": "Different doses (specific amounts not stated).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:07.982596+00:00"}
{"study_id": 22903, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine the effects of magnesium-L-threonate on the gut microbiota and serum metabolome in Alzheimer's disease model mice, as well as its potential to repair intestinal barrier dysfunction.", "results_summary": "Magnesium-L-threonate modulated gut microbiota composition (increasing Bifidobacterium and Turicibacter, decreasing Allobaculum), enriched serum metabolites linked to neurodegenerative disease pathways, and repaired intestinal barrier dysfunction in APP/PS1 mice.", "population_specificity": "Double-transgenic Alzheimer's disease model mice (APP/PS1).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:09.468545+00:00"}
{"study_id": 22904, "supplement_id": 1269, "safety_score": "80", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to evaluate whether magnesium-L-threonate supplementation could prevent persistent pain and improve related outcomes (mood, sleep, cognition) in breast cancer survivors after surgery.", "results_summary": "Magnesium-L-threonate did not significantly reduce chronic pain incidence or improve pain, mood, sleep, or cognitive function compared to placebo. No significant differences were observed between the treatment and control groups on any measured outcomes.", "population_specificity": "Breast cancer survivors who underwent mastectomy (109 patients, 48 in treatment group, 61 in placebo group).", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:12.195064+00:00"}
{"study_id": 22905, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of magnesium deficiency in surgery-induced chronic pain and negative emotion and evaluate the therapeutic effects of oral magnesium-L-Threonate (L-TAMS) in a rat model.", "results_summary": "L-TAMS administration increased serum and CSF magnesium levels, reversed mechanical allodynia and anxiodepressive-like behaviors, and suppressed glial activation and proinflammatory cytokine expression in SMIR-injured rats, but had no effect in sham rats.", "population_specificity": "Rats subjected to skin/muscle incision and retraction (SMIR) surgery.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:13.314702+00:00"}
{"study_id": 22907, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 65, "study_goal": "The researchers aimed to investigate the effects of magnesium L-threonate (MgT) on learning ability and memory in mice intoxicated with lead acetate.", "results_summary": "MgT supplementation did not significantly improve learning and memory in lead-intoxicated mice compared to the control group, though it did potentiate catalase activity in brain tissue. Lead concentration in brain tissue was not significantly affected by MgT.", "population_specificity": "Male Swiss albino mice", "effective_dosage": "100 mg/kg body weight", "study_duration": "40-day treatment period", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:14.300030+00:00"}
{"study_id": 22908, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether chronic oral administration of magnesium-L-threonate (L-TAMS) could prevent memory and emotional deficits induced by oxaliplatin (OXA) in a rodent model.", "results_summary": "L-TAMS prevented OXA-induced memory deficits, anxiety-like and depression-like behaviors, synaptic dysfunction, and downregulation of the NR2B subunit in the hippocampus. It also inhibited OXA-induced upregulation of TNF-\u03b1 and p-p65, as well as microglial activation.", "population_specificity": "Rodents (mice or rats, not specified) treated with oxaliplatin.", "effective_dosage": "604 mg/kg per day", "study_duration": "From 2 days before OXA administration until the end of experiments (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:15.560731+00:00"}
{"study_id": 22909, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether magnesium L-threonate (MgT) could protect against hypoxic injuries, improve cognitive function, and modulate glutamate transporter expression compared to MgSO4.", "results_summary": "MgT pre-treatment significantly increased cell viability under hypoxia, preserved memory in zebrafish, reduced cerebral infarction, and upregulated EAAT4 protein expression.", "population_specificity": "Human SH-SY5Y neurons and zebrafish.", "effective_dosage": "1 mM and 10 mM MgT.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:15.563108+00:00"}
{"study_id": 22906, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether Magnesium-L-threonate (MgT) could suppress oxidative stress damage in A\u03b225-35-treated HT22 cells and an Alzheimer's disease (AD) mouse model, and to explore its neuroprotective mechanisms.", "results_summary": "MgT significantly improved cell viability, reduced ROS levels and apoptosis in HT22 cells, and ameliorated cognitive deficits and neuronal apoptosis in APP/PS1 mice. It also modulated key proteins involved in oxidative stress and apoptosis, including HIF-1\u03b1, NOX4, Bcl-2, Bax, and the PI3K/Akt pathway.", "population_specificity": "A\u03b225-35-treated HT22 cells and APPswe/PS1dE9 (APP/PS1) transgenic mice.", "effective_dosage": "Not specified for HT22 cells; oral administration daily for mice (exact dosage not mentioned).", "study_duration": "12 hours for HT22 cells; 3 months for mice.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:16.984394+00:00"}
{"study_id": 22910, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to verify the protective effect of magnesium-L-threonate (MgT) in a mouse model of Parkinson's disease (PD) induced by MPTP, compared to MgSO4.", "results_summary": "MgT increased magnesium levels in cerebrospinal fluid (CSF), attenuated MPTP-induced motor deficits, reduced dopamine neuron loss, and inhibited iNOS expression, while MgSO4 did not show these effects.", "population_specificity": "C57BL/6J mice", "effective_dosage": "Not specified", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:17.165942+00:00"}
{"study_id": 22911, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the dose-dependent effects of Magnesium-L-threonate (MgT) with other magnesium salts on memory and depression-related behaviors in rats.", "results_summary": "MgT significantly improved memory and reduced depression-like symptoms in rats compared to controls, with biochemical analysis showing increased plasma Mg levels, enhanced cholinergic function, and reduced oxidative stress. The study identified MgT (100mg/kg) as the most effective dose for improving brain-related functions.", "population_specificity": "Adult healthy rats", "effective_dosage": "50 mg/kg, 100 mg/kg, and 150 mg/kg", "study_duration": "28 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:20.214139+00:00"}
{"study_id": 22912, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the unique role of threonate in L-TAMS, specifically whether it directly elevates intraneuronal Mg(2+) and why Mg(2+) alone is ineffective for cognitive enhancement.", "results_summary": "The study found that threonate elevates CSF threonate levels, increases intracellular Mg(2+), upregulates NR2B-containing NMDAR expression, boosts mitochondrial membrane potential, and enhances synapse density in neurons. These effects were unique to threonate and mediated through glucose transporters.", "population_specificity": "Young rats, aging rats, Alzheimer's disease model mice, older adults (human clinical trial), cultured hippocampal neurons, and human neural stem cell-derived neurons.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:22.131741+00:00"}
{"study_id": 22913, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether chronic oral application of magnesium L-threonate (MgT) could prevent or restore short-term memory deficits induced by chronic neuropathic pain in rats and investigate the underlying mechanisms.", "results_summary": "Chronic oral MgT prevented and restored short-term memory deficits and hippocampal long-term potentiation impairments in rats with neuropathic pain, likely by reversing NMDAR dysfunction and normalizing TNF-\u03b1 expression.", "population_specificity": "Adult male rats with spared nerve injury (SNI), a model of chronic neuropathic pain.", "effective_dosage": "609 mg/kg/day via drinking water.", "study_duration": "2 weeks (starting either one week before or after SNI).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:22.700363+00:00"}
{"study_id": 22915, "supplement_id": 1269, "safety_score": "90", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to measure the bioavailability of calcium L-threonate using a double-label stable isotope method to evaluate its potential as a calcium supplement.", "results_summary": "The study found that calcium L-threonate had a bioavailability of 26.49 \u00b1 9.39% in healthy subjects, with calcium balance achieved by 24 hours after dosing. No serious adverse events were reported.", "population_specificity": "14 healthy Chinese subjects", "effective_dosage": "300 mg calcium L-threonate tablets containing 40 mg (44)Ca, administered once", "study_duration": "48 hours (urine collection periods up to 48 hours post-dose)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:23.287032+00:00"}
{"study_id": 22914, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether magnesium-L-threonate (MgT) enhances the extinction of conditioned taste aversion (CTA) and reduces spontaneous recovery in rats.", "results_summary": "MgT-treated rats retained a stronger CTA initially but showed faster extinction and reduced spontaneous recovery of the aversion, suggesting MgT enhances consolidation/retention of CTA and improves extinction efficacy.", "population_specificity": "Adult male Sprague-Dawley rats", "effective_dosage": "16 mg/ml MgT in saccharin solution (CS) and supplemental water+MgT solution", "study_duration": "31 days of MgT treatment, followed by 14 additional days for some groups", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:23.668801+00:00"}
{"study_id": 22917, "supplement_id": 1269, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "To evaluate the clinical efficacy and side effects of ferrous L-threonate in treating iron deficiency anemia (IDA) compared to ferrous succinate.", "results_summary": "Ferrous L-threonate showed significant and rapid efficacy in treating IDA, with hemoglobin levels rising steadily and peaking at week 8. Side effects were minimal and comparable to the control group (ferrous succinate).", "population_specificity": "140 IDA patients diagnosed according to standard criteria across three hospitals.", "effective_dosage": "Not specified", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:24.350754+00:00"}
{"study_id": 22916, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether L-threonate could attenuate DHT-induced DKK-1 expression and reverse DHT-inhibited growth of outer root sheath keratinocytes, suggesting its potential as a treatment for androgen-driven balding.", "results_summary": "L-threonate attenuated DHT-induced DKK-1 expression in dermal papilla cells and reversed DHT-inhibited growth of outer root sheath keratinocytes, indicating its potential to prevent androgen-driven balding.", "population_specificity": "Cultured dermal papilla cells and outer root sheath keratinocytes (in vitro study).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:25.043536+00:00"}
{"study_id": 192587, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers were attempting to determine the bioavailability of magnesium L-threonate compared to other magnesium supplements.", "results_summary": "The study found that magnesium L-threonate has higher bioavailability compared to other magnesium supplements, suggesting it may be more effective. No specific efficacy outcomes or clinical results were detailed in the abstract.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:27.200244+00:00"}
{"study_id": 192588, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were investigating the role of MAGT1 deficiency in XMEN disease, focusing on impaired magnesium regulation and its impact on immune function, particularly EBV infection and NKG2D expression.", "results_summary": "The study found that MAGT1 deficiency leads to impaired magnesium regulation, resulting in decreased EBV-cytotoxicity and reduced surface expression of NKG2D on CD8+ T cells.", "population_specificity": "Patients with XMEN disease (X-linked MAGT1 deficiency).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:29.884260+00:00"}
{"study_id": 192589, "supplement_id": 1269, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether magnesium L-threonate (MgT) could enhance synaptic plasticity and memory functions by upregulating NR2B expression in the brain.", "results_summary": "The study found that MgT effectively upregulated NR2B expression, improved synaptic plasticity, and enhanced memory functions in preclinical studies, with potential benefits for age-related memory loss.", "population_specificity": "Rodents (preclinical studies)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:30.202900+00:00"}
{"study_id": 22336, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether dietary L-tyrosine could alleviate ASD-like behavioral disorders in a VPA-induced ASD mouse model and explore the underlying mechanisms.", "results_summary": "L-tyrosine supplementation significantly reduced ASD-like behaviors, improved social communication, decreased repetitive behavior, attenuated neuronal loss in hippocampal regions, and modified gut microbiota composition. Microbiota transplantation from L-tyrosine-treated mice replicated these protective effects in ASD mice.", "population_specificity": "Valproic acid (VPA)-induced ASD mouse model", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:31.838266+00:00"}
{"study_id": 22335, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to validate an automated segmentation network for [18F]FET PET scans in glioblastoma patients, comparing its performance with expert physician assessments.", "results_summary": "The automated segmentation showed excellent correlation with physician-derived metrics (BTV and TBRmean) but underestimated tumor volumes and had occasional erroneous segmentations, potentially impacting radiotherapy planning. Spatial and distance-based metrics indicated strong overlap, though further training on local datasets was recommended for broader implementation.", "population_specificity": "Twenty-four glioblastoma patients undergoing [18F]FET PET scans (52 total scans across preradiotherapy, retest, and follow-up phases).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:32.021133+00:00"}
{"study_id": 22337, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to determine if functional connectivity between recurrent glioma regions and resting-state brain networks, assessed via FET PET and functional MRI, could serve as a prognostic biomarker for overall survival.", "results_summary": "The study found that higher functional connectivity between tumor regions and specific resting-state networks (e.g., dorsal attention network) was independently associated with longer overall survival, particularly in glioblastoma patients. Tumor grade and IDH mutation status were also strong predictors of survival.", "population_specificity": "82 patients (ages 26-81) with recurrent gliomas (glioblastoma, astrocytoma, oligodendroglioma) post-therapy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:32.948636+00:00"}
{"study_id": 22334, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether GE-SE EPIK-derived parameters (OEF/T2/T2*/vCBV) could characterize metabolic activity in tumor regions identified by [18F]fluoroethyl-L-tyrosine (FET) PET, serving as a surrogate for neoplastic tissue.", "results_summary": "The study found that GE-SE EPIK-derived parameters (T2/T2*/vCBV/OEF) were sensitive to changes in tumor regions identified by FET-PET and FLAIR thresholds, with some parameters able to distinguish between tumor types. However, susceptibility artifacts in T2*/OEF maps limited qualitative interpretation.", "population_specificity": "Fifty-seven brain tumor patients (31 female, 26 male; age 27-73 years) with 66 histologically confirmed lesions (glioblastoma, astrocytoma, metastasis, oligodendroglioma).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:34.495388+00:00"}
{"study_id": 22338, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the frequency of borderline cases in 18F-FET PET scans and evaluate the role of quantitative parameters in differentiating tumor relapse from treatment-related changes in glioma patients.", "results_summary": "The study found that 31% of patients had borderline 18F-FET PET findings, with quantitative parameters like TBR showing high accuracy in clearly positive or negative cases but lower reliability in borderline cases. Adjusting TBR cutoff values by \u00b110% improved diagnostic performance.", "population_specificity": "Patients with pretreated gliomas suspected of tumor relapse (n = 439).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:35.029920+00:00"}
{"study_id": 22340, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the mechanisms of antiviral action of dihalogenated L-tyrosine derivatives (dH-Y) against chikungunya virus (CHIKV) infection.", "results_summary": "The study found that six dH-Y compounds exhibited varying antiviral effects against CHIKV, with C3 showing inhibition at multiple stages of the viral replicative cycle. Some compounds reduced viral protein expression, genome replication, or infectious particle production, while others affected viral adhesion or internalization.", "population_specificity": "In vitro cell cultures and in silico models.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:38.606749+00:00"}
{"study_id": 22339, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to compare the effectiveness of [18F]FET PET and contrast-enhanced MRI for early response assessment in patients with recurrent high-grade astrocytic glioma treated with nivolumab and bevacizumab.", "results_summary": "The study found that [18F]FET PET was superior to MRI for early response assessment, with significant predictors of response including lower metabolically active volume (MTV), larger decreases in MTV and TBRmax, and smaller PRM progressive volume. MRI-based measures did not predict response as effectively.", "population_specificity": "Patients with nonresectable first recurrence of high-grade astrocytic glioma after EORTC/NCIC protocol.", "effective_dosage": "Not specified", "study_duration": "2 cycles of treatment (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:39.259164+00:00"}
{"study_id": 22341, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "To assess the utility of [18F]fluoroethyl-L-tyrosine PET co-registered with MRI in localizing difficult-to-detect prolactinomas to inform clinical and surgical decision-making.", "results_summary": "[18F]FET-PET/MRICR identified lesions in 14/17 patients, influenced clinical decisions in 15/17, and showed concordance with conventional MRI in 10/17 cases. Treatment goals were achieved in 7/8 surgical patients, with remission in 5/7 where total resection was feasible.", "population_specificity": "17 patients with difficult-to-localize prolactinomas or unclear adenomas on conventional MRI.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:39.704526+00:00"}
{"study_id": 22344, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the potential benefits of L-Tyrosine supplementation in improving muscle strength in an infant diagnosed with nemaline rod myopathy.", "results_summary": "The infant showed significant improvement in muscle strength after starting dietary L-Tyrosine supplementation, suggesting its potential role in supportive care for nemaline rod myopathy.", "population_specificity": "An infant with nemaline rod myopathy caused by compound heterozygous variants in the NEB gene.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:40.144043+00:00"}
{"study_id": 22343, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine the impact of L-tyrosine ingestion on stress markers and cognitive performance during a mental stress challenge involving a virtual reality active shooter drill and cognitive tasks.", "results_summary": "L-tyrosine did not affect stress markers but significantly reduced missed responses during the Stroop challenge compared to placebo, suggesting a potential cognitive performance benefit under stress.", "population_specificity": "80 subjects (age 21 \u00b1 2.6 years; 46 male, 34 female)", "effective_dosage": "2000 mg (single dose)", "study_duration": "Single administration prior to stress challenge", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:40.773417+00:00"}
{"study_id": 192367, "supplement_id": 1268, "safety_score": "90", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the long-term safety and efficacy of BH4 therapy combined with L-Dopa and 5-hydroxytryptophan in treating BH4 deficiency.", "results_summary": "The study found that BH4 therapy, combined with L-Dopa and 5-hydroxytryptophan, effectively reduced serum phenylalanine levels and demonstrated excellent long-term safety with no reported side effects.", "population_specificity": "19 patients with BH4 deficiency (17 with 6-pyruvoyl tetrahydropterin synthase deficiency and 2 with dihydropteridine reductase deficiency), treated before age 4.", "effective_dosage": "Not specified for L-Dopa (BH4 mean dose: 5 mg/kg per day).", "study_duration": "Mean duration of BH4 therapy was 13.2 years (follow-up \u226428 years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:42.983135+00:00"}
{"study_id": 22346, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the feasibility of incorporating FET PET-derived biological tumour volumes (BTVs) into target volume delineation for glioblastoma management by Radiation Oncologists.", "results_summary": "The study found that hybrid target volumes (TVMR+FET) were significantly larger than standard volumes (TVMR) and showed greater spatial overlap and boundary agreement for gross tumour volumes (GTVs). All sites successfully passed the planning exercise, demonstrating feasibility in credentialing Radiation Oncologists for FET PET-based delineation.", "population_specificity": "Newly diagnosed glioblastoma patients in Australia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:43.724044+00:00"}
{"study_id": 22345, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the interaction of Cold Atmospheric Plasma (CAP) with L-Tyrosine, hypothesizing the creation of novel supramolecular structures and examining CAP-induced transformations in L-Tyrosine self-assembled structures.", "results_summary": "The study found that CAP treatment led to the formation of oxygenated and nitro derivatives of L-Tyrosine, as well as enhanced surface size and novel nanomaterial-shaped assemblies in self-assembled structures. These changes suggest potential advancements in biomimetic nanomaterial fabrication.", "population_specificity": "Not specified (in vitro study on L-Tyrosine-derived structures)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:43.891655+00:00"}
{"study_id": 22348, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the clinical value of O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) PET in diagnosing glioblastoma recurrence.", "results_summary": "The study found that 18F-FET-PET reliably confirmed glioblastoma recurrence in all re-operated patients, with similar static and kinetic parameters regardless of MGMT status, suggesting its utility in selecting patients for salvage surgery.", "population_specificity": "Patients with suspected recurrent glioblastoma considered suitable for salvage surgery.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:46.538966+00:00"}
{"study_id": 22347, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the diagnostic value of 18F-fluoroethyl-tyrosine (18F-FET) PET in differentiating glioma progression from therapy-related changes in post-treatment patients.", "results_summary": "The study found that 18F-FET PET has high diagnostic value for distinguishing viable tumor tissue from pseudoprogression or therapy-related changes, especially when combining traditional visual analysis with radiomics. It highlighted the compound's ability to accumulate in glioma cells independently of blood-brain barrier disruption.", "population_specificity": "Glioma patients post-therapeutic intervention.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:46.732594+00:00"}
{"study_id": 22349, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the antiviral potential of synthetic di-halogenated compounds derived from L-Tyrosine against HIV-1 strains.", "results_summary": "Four compounds (TODB-2M, TODC-2M, TODC-3M, YDC-3M) showed low toxicity and significant inhibitory activity against HIV-1, potentially interacting with reverse transcriptase, viral protease, or envelope gp120.", "population_specificity": "In vitro and in silico models (HIV-1 R5 and X4 strains, pseudotyped virus, PBMCs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:47.922265+00:00"}
{"study_id": 22350, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether L-tyrosine preloading enhances the uptake of 4-borono-L-phenylalanine (BPA) in human non-small cell lung carcinoma (A549) and normal Chinese hamster lung fibroblast (V79-4) cells.", "results_summary": "L-tyrosine preloading increased BPA uptake in V79-4 cells by 2.04-fold and in A549 cells by 1.24-fold, with statistical significance. SC-ICP-MS revealed heterogeneity in boron content within A549 cells, indicating varied responses to BPA exposure.", "population_specificity": "Human non-small cell lung carcinoma (A549) and normal Chinese hamster lung fibroblast (V79-4) cell models.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:49.202855+00:00"}
{"study_id": 22351, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the impact of FET-PET imaging (using O-(2-[18F]-fluoroethyl)-L-tyrosine) on radiotherapy planning and its accuracy in distinguishing pseudoprogression from true tumor progression in glioblastoma patients.", "results_summary": "The study evaluates FET-PET's role in improving radiotherapy volume delineation and differentiating pseudoprogression from tumor progression, with secondary outcomes assessing its prognostic value and health economic impact. Results are pending as the study is prospective and ongoing.", "population_specificity": "Adults aged \u226518 years with newly diagnosed glioblastoma across 10 Australian sites.", "effective_dosage": "Not specified (FET-PET imaging performed at up to three time points).", "study_duration": "Not specified (follow-up tied to clinical progression).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:49.375841+00:00"}
{"study_id": 22352, "supplement_id": 1270, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if L-tyrosine could reduce mycobacterial survival in granulomas and macrophages, and its potential as a treatment for tuberculosis.", "results_summary": "L-tyrosine reduced Mycobacterium marinum levels in zebrafish larvae and adults, inhibited intracellular pathogen survival, and upregulated IFN-\u03b3 expression in infected adults. It appeared to inhibit Mtb survival by promoting ROS production.", "population_specificity": "Mycobacterium marinum-infected zebrafish (larvae and adults)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:22:50.422520+00:00"}
